




(86) Date de dépôt PCT/PCT Filing Date: 1991/10/17
(87) Date publication PCT/PCT Publication Date: 1992/04/30
(45) Date de délivrance/Issue Date: 2008/01/15
(85) Entrée phase nationale/National Entry: 1993/04/05
(86) N° demande PCT/PCT Application No.: US 1991/007611
(87) N° publication PCT/PCT Publication No.: 1992/006990
(30) Priorité/Priority: 1990/10/17 (US07/599,491)

(51) Cl.Int./Int.Cl. *C12N 15/49* (2006.01),
A61K 39/00 (2006.01), *A61K 39/21* (2006.01),
C07K 14/16 (2006.01), *C12N 15/867* (2006.01),
C12N 5/10 (2006.01), *C12N 7/01* (2006.01),
C12P 21/00 (2006.01), *C12Q 1/70* (2006.01),
G01N 33/569 (2006.01)

(72) Inventeurs/Inventors:
REITZ, MARVIN S., JR., US;
MARKHAM, PHILLIP D., US;
GALLO, ROBERT C., US;
LORI, FRANCO C., US;
POPOVIC, MIKULAS, US;
...

(73) Propriétaire/Owner:

(54) Titre : CLONES MOLECULAIRES DU VIH-1 ET LEUR USAGE
(54) Title: MOLECULAR CLONES OF HIV-1 AND USES THEREOF



(57) Abrégé/Abstract:

The present invention relates to the HIV-1 strains MN-ST1 and BA-L which are typical United States HIV-1 isotypes. The present invention relates to DNA segments encoding the envelope protein of MN-ST1 or BA-L, to DNA constructs containing such DNA segments and to host cells transformed with such constructs. The viral isolates and envelope proteins of the present invention are of value for use in vaccines and bioassays for the detection of HIV-1 infection in biological samples, such as blood bank samples.



(72) **Inventeurs(suite)/Inventors(continued):** GARNTER, SUZANNE, US; FRANCHINI, GENOVEFFA, US

(73) **Propriétaires(suite)/Owners(continued):**

GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE
DEPARTMENT OF HEALTH AND HUMAN SERVICES, US

(74) **Agent:** GOWLING LAFLEUR HENDERSON LLP

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07H 15/12, C12N 5/10, 7/02 C12N 7/04, 15/49, C07K 3/12 C07K 13/00, 17/00, C12Q 1/70 A61K 39/10, G01N 33/53 2093427 A1	(11) International Publication Number: WO 92/06990 (43) International Publication Date: 30 April 1992 (30.04.92)
(21) International Application Number: PCT/US91/07611 (22) International Filing Date: 17 October 1991 (17.10.91) (30) Priority data: 599,491 17 October 1990 (17.10.90) US (71) Applicant: THE UNITED STATES OF AMERICA, represented by THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE [US/US]; Washington, DC 20231 (US). (72) Inventors: REITZ, Marvin, S., Jr. ; 17833 Bowie Mill Road, Derwood, MD 20855 (US). FRANCHINI, Genoveffa ; 4400 17th Street, N.W., Washington, DC 20011 (US). MARKHAM, Phillip, D. ; 17008 Glen Oak Run, Rockville, MD 20855 (US). GALLO, Robert, C. ; 8513 Thornden Terrace, Bethesda, MD 20817 (US). LORI, Franco, C. ; 5517 Southwick Street, Bethesda, MD 20817 (US). POPOVIC, Mikulas ; 9917 Holmhurst Road, Bethesda, MD 20817 (US). GARNTER, Suzanne ; 14512 Cartwright Way, N. Potomac, MD 20878 (US).	(74) Agents: OLIFF, James, A. et al.; Oliff & Berridge, P.O. Box 19928, Alexandria, VA 22320 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i>
(54) Title: MOLECULAR CLONES OF HIV-1 AND USES THEREOF (57) Abstract The present invention relates to the HIV-1 strains MN-ST1 and BA-L which are typical United States HIV-1 isotypes. The present invention relates to DNA segments encoding the envelope protein of MN-ST1 or BA-L, to DNA constructs containing such DNA segments and to host cells transformed with such constructs. The viral isolates and envelope proteins of the present invention are of value for use in vaccines and bioassays for the detection of HIV-1 infection in biological samples, such as blood bank samples.	

MOLECULAR CLONES OF HIV-1 AND USES THEREOFBACKGROUND OF THE INVENTION

HIV-1 has been identified as the etiologic agent of the acquired immunodeficiency syndrome (AIDS) (Barre-Sinoussi et al., Science 220, 868-871, 1983; Popvic et al., Science 224, 497-500, 1984; Gallo et al., Science 224, 500-503, 1984). Infected individuals generally develop antibodies to the virus within several months of exposure (Sarngadharan et al., Science 224, 506-508, 1984), which has made possible the development of immunologically based tests which can identify most blood samples from infected individuals. This is a great advantage in diagnosis, and is vital to maintaining the maximum possible safety of samples from blood banks.

An important aspect of HIV-1 is its genetic variability (Hahn et al., Proc. Natl. Acad. Sci. U.S.A. 82, 4813-4817, 1985). This is particularly evident in the gene for the outer envelope glycoprotein (Starcich et al., Cell 45, 637-648, 1986; Alizon et al., Cell 46, 63-74, 1986; Gurgo et al., Virology 164, 531-536, 1988). Since the outer envelope glycoprotein is on the surface of the virus particle and the infected cell, it is potentially one of the primary targets of the immune system, including the target of neutralizing antibodies and cytotoxic T cells. This variability may also lead to differences in the ability of antigens from different strains of HIV-1 to be recognized by antibodies from a given individual, as well as to differences in the ability of proteins from different strains of virus to elicit an immune response which would be protective against the mixture of virus strains that exists in the at risk populations.

Several biologically active complete molecular clones of various strains of HIV-1 have been obtained and sequenced. These clones, however, seem to represent viral genotypes which are relatively atypical of United States HIV-1 isolates. In addition, several of the translational reading frames for non-structural viral proteins are not complete. Further, viruses derived from these clones do

2093427

not grow in macrophages, in contrast to many HIV-1 field isolates and, perhaps, because of this lack of ability to infect macrophages efficiently, these clones do not replicate well in chimpanzees. This latter ability is important for testing candidate vaccines in animal systems. In addition, the ability to infect macrophages is critical in evaluating the possible protective efficacy of elicited immune response since neutralization of infectivity on macrophage may differ from the better studied neutralization on T cells.

Neutralizing antibodies (Robert-Guroff et al., Nature 316, 72-74, 1985; Weiss et al., Nature 316, 69-72, 1985) have been demonstrated in infected individuals, as have cytotoxic T cells responses (Walker et al., Nature 328, 345-348, 1988). Although these do not appear to be protective, it is likely that if they were present prior to infection, they would prevent infection, especially by related strains of virus. This is supported by the finding that macaques can be protected by immunization with inactivated simian immunodeficiency virus (SIV) from infection with the homologous live virus (Murphy-Corb et al., Science 246, 1293-1297, 1989). Chimps also have been passively protected against challenge by live virus by prior administration of neutralizing antibodies to the same virus (Emini et al., J. Virol. 64, 3674-3678, 1989). One problem, however, is that at least some of the neutralizing antibodies studied depend on recognition of a variable region on the envelope (Matsushita et al., J. Virol. 62, 2107-2114, 1988; Rusche et al., Proc. Natl. Acad. Sci. U.S.A. 85, 3198-3202, 1988; Skinner et al., AIDS Res. Hum. Retroviruses 4, 187-197, 1988) called the V3 region (Starcich et al., Cell 45, 637-648, 1986).

An at least partial solution to the problem of viral heterogeneity is to identify prototypical HIV-1 strains, that is, those that are most similar by DNA sequence data or serologic reactivity to strains present in the population at risk. The inclusion of a limited number of such prototype strains in a polyvalent vaccine

2093427
3

cocktail might then result in elicitation of an immune response protective against most naturally occurring viruses within a given population. Such a mixture should also provide the maximum possible sensitivity in diagnostic tests for antibodies in infected individuals.

Components of highly representative isolates of a geographical area provide the maximum possible sensitivity in diagnostic tests and vaccines. Production of viral proteins from molecular clones by recombinant DNA techniques is the preferred and safest means to provide such proteins. Molecular clones of prototype HIV-1 strains can serve as the material from which such recombinant proteins can be made. The use of recombinant DNA avoids any possibility of the presence of live virus and affords the opportunity of genetically modifying viral gene products. The use of biologically active clones ensures that the gene products are functional and hence, maximizes their potential relevance.

Infectious clones, that is, those which after transfection into recipient cells produce complete virus, are desirable for several reasons. One reason is that the gene products are by definition functional; this maximizes their potential relevance to what is occurring in vivo. A second reason is that genetically altered complete virus is easy to obtain. Consequently, the biological consequences of variability can be easily assessed. For example, the effect of changes in the envelope gene on the ability of the virus to be neutralized by antibody can be easily addressed. Using this technique, a single point mutation in the envelope gene has been shown to confer resistance to neutralizing antibody (Reitz et al., Cell 54, 57-63, 1988). A third reason is that a clonal virus population provides the greatest possible definition for challenge virus in animals receiving candidate vaccines, especially those including components of the same molecularly cloned virus.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide vaccine components for an anti HIV-1 vaccine which would represent a typical United States isolate HIV-1.

5 It is another object of the present invention to provide diagnostic tests for the detection of HIV-1.

Various other objects and advantages of the present invention will become apparent from the drawings and the following description of the invention.

10 BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 shows the structure and restriction map of the lambda MN-PH1 clone.

FIGURE 2 shows the restriction map of the MN-PH1 envelope plasmid clone.

15 FIGURE 3 shows the restriction map and structure of the lambda MN-ST1 clone.

FIGURE 4 shows the structure of the lambda BA-L clone.

20 FIGURE 5 shows the restriction map of the clone BA-L1.

Detailed Disclosure of the Invention

The present invention relates to the HIV-1 virus strains, MN-ST1 and BA-L, which are more typical of the HIV-1 isolates found in the United States than previously known HIV-1 strains. Local isolates provide better material for vaccine and for the detection of the virus in biological samples, such as blood bank samples.

25 The present invention relates to DNA segments encoding the env protein of MN-ST1 or BA-L (the DNA sequence given in Tables II and III respectively being two such examples) and to nucleotide sequences complementary to the segments referenced above as well as to other genes and nucleotide sequences contained in these clones. The present invention also relates to DNA segments encoding a unique portion of the MN-ST1 env protein or the BA-L env protein. (A "unique portion" consists of at least five (or six) amino acids or corresponding at least 15 (or 18) nucleotides.)

5 2093427

The invention further relates to the HIV-1 virus strains MN-ST1 and BA-L themselves. The HIV-1 virus strains of the present invention are biologically active and can easily be isolated by one skilled in the art using known methodologies.

The above-described DNA segments of the present invention can be placed in DNA constructs which are then used in the transformation of host cells for a generation of recombinantly produced viral proteins. DNA constructs of the present invention comprise a DNA segment encoding the env protein and the flanking region of MN-ST1 (or BA-L) or a portion thereof and a vector. The constructs can further comprise a second DNA segment encoding both a rev protein and a rev-responsive region of the env gene operably linked to the first DNA segment encoding the env protein. The rev protein facilitates efficient expression of the env protein in eucaryotic cells. Suitable vectors for use in the present invention include, but are not limited to, pSP72, lambda EMBL3 and SP65gpt.

Host cells to which the present invention relates are stably transformed with the above-described DNA constructs. The cells are transformed under conditions such that the viral protein encoded in the transforming construct is expressed. The host cell can be procaryotic (such as bacterial), lower eucaryotic (such as fungal, including yeast) or higher eucaryotic (such as mammalian). The host cells can be used to generate recombinantly produced MN-ST1 (or BA-L) env protein by culturing the cells in a manner allowing expression of the viral protein encoded in the construct. The recombinantly produced protein is easily isolated from the host cells using standard protein isolation protocols.

Since HIV-1 strains MN-ST1 and BA-L represent relatively typical United States genotypes, non-infectious MN-ST1 or BA-L proteins (for example, the env protein), peptides or unique portions of MN-ST1 or BA-L proteins (for example, a unique portion of the env protein), and even whole inactivated MN-ST1 or BA-L can be used as an

immunogen in mammals, such as primates, to generate antibodies capable of neutralization and T cells capable of killing infected cells. The protein can be isolated from the virus or made recombinantly from a cloned envelope gene. Accordingly, the virus and viral proteins of the present invention are of value as either a vaccine or a component thereof, or an agent in immunotherapeutic treatment of individuals already infected with HIV-1.

As is customary for vaccines, a non-infectious antigenic portion of MN-ST1 or BA-L, for example, the env protein, can be delivered to a mammal in a pharmacologically acceptable carrier. The present invention relates to vaccines comprising non-infectious antigenic portions of either MN-ST1 or BA-L and vaccines comprising non-infectious antigenic portions of both MN-ST1 and BA-L. Vaccines of the present invention can include effective amounts of immunological adjuvants known to enhance an immune response. The viral protein or polypeptide is present in the vaccine in an amount sufficient to induce an immune response against the antigenic protein and thus to protect against HIV-1 infection. Protective antibodies are usually best elicited by a series of 2-3 doses given about 2 to 3 weeks apart. The series can be repeated when circulating antibody concentration in the patient drops.

Virus derived from the infectious HIV-1(MN) clones, MN-ST1, may also be used for reproducible challenge experiments in chimpanzees treated with candidate HIV-1 vaccines or in vitro with human antiserum from individuals treated with candidate vaccines. A candidate vaccine can be administered to a test mammal, such as a chimpanzee prior to or simultaneously with the infectious MN-ST1 virus of the present invention. Effectiveness of the vaccine can be determined by detecting the presence or absence of HIV-1 infection in the test mammals. Side-by-side comparative tests can be run by further administering to a second set of test mammals the virus alone and comparing the number of infections which develop in the two sets of test mammals. Alternatively, candidate

WO 92/06990

PCT/US91/07611

7

vaccines can be evaluated in humans by administering the vaccine to a patient and then testing the ability of the MN-ST1 virus to infect blood cells from the patient.

5 The present invention also relates to the detection of HIV-1 virus in a biological sample. For detection of an HIV-1 infection, the presence of the virus, proteins encoded in the viral genome, or antibodies to HIV-1 is determined. Many types of tests, as one skilled in the art will recognize, can be used for detection. Such tests
10 include, but are not limited to, ELISA and RIA.

In one bioassay of the present invention all, or a unique portion, of the env protein is coated on a surface and contacted with the biological sample. The presence of a resulting complex formed between the protein and anti-
15 bodies specific therefor in the serum can be detected by any of the known methods commonly used in the art, such as, for example, fluorescent antibody spectroscopy or colorimetry.

The following non-limiting examples are given to
20 further demonstrate the present invention without being deemed limitative thereof.

EXAMPLES

MN-PH1 Clone

The permuted circular unintegrated viral DNA representing the
25 complete HIV-1 (MN) genome cloned by standard techniques (Sambrook et al., 1989, Molecular Cloning. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press) into the Eco RI site of lambda gtWES.lambda B DNA from total DNA of H9 cells producing HIV-1(MN). This clone is designated lambda MN-PH1, and its structure and
30 restriction map are shown in Figure 1. The clone was subcloned into M13mp18 and M13mp19, and the DNA sequence shown unpermuted in Table I, of the entire clone, given in Figure 1, was obtained by the dideoxy chain termination method (Sanger et al., Proc. Natl. Acad. Sci. U.S.A. 74, 5463-5467, 1977). The amino acid sequence of the
35 envelope protein (see Table I and Table IA) was inferred from the DNA sequence. A restriction map of the cloned unintegrated viral DNA (see

WO 92/06990

PCT/US91/07611

8

Figure 1) was also obtained from the DNA sequence of lambda PH1 and used in conjunction with the inferred amino acid sequence of the viral proteins to subclone the envelope (env) gene into the commercially available plasmid pSP72 (Promega Biological Research Products, Madison, WI), as shown in Figure 2. This plasmid (pMN-PH1env) contains, in addition to the coding regions for the envelope proteins, the coding region for the rev protein (Feinberg et al., Cell 46, 807-817, 1986) and the portion of the env gene which contains the rev-responsive region (Dayton et al., J. Acquir. Immune. Defic. Syndr. 1, 441-452, 1988), since both are necessary for efficient expression of the envelope protein in eucaryotic cells. This plasmid thus contains all the elements required for production of envelope protein following placement into appropriate expression vectors and introduction into recipient cells, all by standard techniques known to molecular biologists.

MN-ST1 Clone

The infectious molecular clone, lambda MN-ST1, was obtained by cloning integrated provirus from DNA purified from peripheral blood lymphocytes infected with HIV-1(MN) and maintained in culture for a short time (one month). The integrated proviral DNA was partially digested with the restriction enzyme Sau3A under conditions which gave a maximum yield of DNA fragments of from 15-20 kilobases (kb). This was cloned into the compatible BamHI site of lambda EMBL3, as shown in Figure 3. Figure 3 also shows the restriction map of clone lambda MN-ST1. The DNA sequence of the entire clone, given in Table II, was obtained by the dideoxy chain termination method (Sanger et al., Proc. Natl. Acad. Sci. U.S.A. 74, 5463-5467, 1977). The amino acid sequence was predicted from the DNA sequence (see Tables II and IIA). This clone can be transfected into recipient cells by standard techniques. After transfection, the cloned proviral DNA is expressed into biologically active virus particles, which can be used as a source for virus stocks. The proviral DNA whose

restriction map is shown in Figure 2, was removed from the lambda phage vector by digestion with BamHI and inserted into a plasmid, SP65gpt (Feinberg et al., Cell 46, 807-817, 1986). This plasmid, pMN-ST1, contains an SV40 origin of replication. Consequently, transfection into COS-1 cells (Gluzman, Y. Cell 23, 175-182, 1981), which produce a SV40 gene product which interacts with the cognate origin of replication, results in a transient high plasmid copy number with a concomitant production of large amount of replication competent, infectious virus (Feinberg et al., Cell 46, 807-817, 1986). This provides a convenient source of genetically homogeneous virus, as well as a way to introduce desired mutations using standard methods.

The envelope gene was excised from the lambda phage clone and cloned into a plasmid as described above for lambda MN-PH1. This clone (pMN-ST1env), is similar to pMN-PH1env, described above, except that it derives from a biologically active cloned provirus. Like pMN-PH1env, it can be placed in a suitable vector and host to produce the envelope protein of HIV-1(MN) by well known techniques.

BA-L Clone

A Hind III fragment of unintegrated viral DNA representing the HIV-1 (BA-L) genome was cloned by standard techniques into lambda phage Charon 28 DNA from total DNA of peripheral blood macrophages infected with and producing HIV-1 (BA-L). A positive clone was selected by hybridization using a radiolabelled probe for the HIV-1 envelope. This clone, designated lambda BA-L1, was found to contain the entire gene for the envelope protein. Its structure is given in Figure 4. The insert was transferred into a plasmid (pBluescript*, Stratagene**, La Jolla, CA) and the DNA sequence of the env gene was determined (see Table III). This clone is designated pBA-L1.

The amino acid sequence of the envelope protein, shown in Tables III and IIIA, was inferred from the DNA sequence. A restriction map was also obtained from the DNA sequence of BA-L1 (shown in Figure 5) in order to determine the

* Trade Mark

appropriate restriction enzyme sites for cloning the env gene into suitable expression vectors. An Eco RI-HindIII fragment of 0.4 Kb and a 2.8 Kb HindIII-XbaI fragment when cloned together constitute the entire env gene. This plasmid contains, in addition to the coding regions for the envelope proteins, the coding region for the rev protein and the portion of the env protein which contains the rev-responsive region. Both are necessary for efficient expression of the envelope protein in eucaryotic cells (Feinberg et al., Cell 46, 807-817, 1986; Dayton et al., J. Acquir. Immune. Defic. Syndr. 1, 441-452). This plasmid thus contains all the HIV-1 genetic elements required for production of envelope protein following placement into appropriate expression vectors and introduction into recipient cells, all by standard techniques well known in the art.

Statement of Deposit

The lambda MN-ST1 clone and the BA-L plasmid clone were deposited at the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852, U.S.A., on September 13, 1990, under the terms of the Budapest Treaty. The lambda MN-ST1 clone has been assigned the ATCC accession number ATCC 40889 and the BA-L plasmid clone has been assigned the ATCC accession number ATCC 40890.

* * * * *

While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be appreciated by one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention.

TABLE I

TGGAAGGGCT	AATTCACCTCC	CAACGAAGAC	AAGATATCCT	TGATCTGTGG	ATCTACCACA	60
CACAAGGCTA	CTTCCCTGAT	TAGCAGAACT	ACACACCAGG	GCCAGGGATC	AGATATCCAC	120
TGACCTTTGG	ATGGTGCTAC	AAGCTAGTAC	CAGTTGAGCC	AGAGAAGTTA	GAAGAAGCCA	180
ACAAAGGAGA	GAACACCAGC	TTGTTACACC	CTGTGAGCCT	GCATGGAATG	GATGACCCGG	240
AGAGAGAAGT	GTTAGAGTGG	AGGTTTGACA	GCCGCCTAGC	ATTTTCATCAC	ATGGCCCGAG	300
AGCTGCATCC	GGAGTACTTC	AAGAACTGCT	GACATCGAGC	TTGCTACAAG	GGACTTTCCG	360
CTGGGGACTT	TCCAGGGAGG	CGTGGCCTGG	GCGGGACTGG	GGAGTGGCGA	GCCCTCAGAT	420
CCTGCATATA	AGCAGCTGCT	TTTTGCCTGT	ACTGGGTCTC	TCTGGTTAGA	CCAGATCTGA	480
GCCTGGGAGC	TCTCTGGCTA	ACTAGGGAAC	CCACTGCTTA	AGCCTCAATA	AAGCTTGCCT	540
TGAGTGCTTC	AAGTAGTGTG	TGCCCCGTCTG	TTATGTGACT	CTGGTAGCTA	GAGATCCCTC	600
AGATCCTTTT	AGGCAGTGTG	GAAAATCTCT	AGCAGTGCGG	CCCGAACAGG	GACTTGAAAG	660
CGAAAGAAAA	ACCAGAGCTC	TCTCGACGCA	GGACTCGGCT	TGCTGAAGCG	CGCACGGCAA	720
GAGGCGAGGG	GCGGCGACTG	GTGAGTACGC	CAAAAATTCT	TGACTAGCGG	AGGCTAGAAG	780
GAGAGAGATG	GGTGCGAGAG	CGTCGGTATT	AAGCGGGGGA	GAATTAGATC	GATGGGAAAA	840
CATTCGGTTA	AGGCCAGGGG	GAAAGAAAAA	ATATAAATTA	AAACATGTAG	TATGGGCAAG	900
CAGGGAGCTA	GAACGATTCTG	CAGTCAATCC	TGGCCTGTTA	GAAACATCAG	AAGGCTGTAG	960
ACAAATACTG	GGACAGCTAC	AACCATCCCT	TCAGACAGGA	TCAGAAGAAC	TTAAATCATT	1020
ATATAATACA	GTAGCAACCC	TCTATTGTGT	GCATCAAAAG	ATAGAGATAA	AAGACACCAA	1080
GGAAGCTTTA	GAGAAAATAG	AGGAAGAGCA	AAACAAAAGT	AAGAAAAAAG	CACAGCAAGC	1140
AGCAGCTGAC	ACAGGAAACA	GAGGAAACAG	CAGCCAAGTC	AGCCAAAATT	ACCCCATAGT	1200
GCAGAACATC	GAGGGGCAAA	TGGTACATCA	GGCCATATCA	CCTAGAACTT	TAAATGCATG	1260
GGTAAAAGTA	GTAGAAGAGA	AGGCTTTCAG	CCCAGAAGTA	ATACCCATGT	TTTCAGCATT	1320
ATCAGAAGGA	GCCACCCAC	AAGATTTAAA	CACCATGCTA	AACACAGTGG	GGGGACATCA	1380
AGCAGCCATG	CAAATGTAA	AAGAGACCAT	CAATGAGGAA	GCTGCAGAAT	GGGATAGATT	1440
GCATCCAGTG	CATGCAGGGC	CTATTACACC	AGGCCAGATG	AGAGAACCAA	GGGGAAGTGA	1500
CATAGCAGGA	ACTACTAGTA	CCCTTCAGGA	ACAAATAGGA	TGGATGACAA	ATAATCCACC	1560
TATCCAGTA	GGAGAAATCT	ATAAAAGATG	GATAATCCTG	GGATTAAATA	AAATAGTAAG	1620
GATGTATAGC	CCTTCCAGCA	TTCTGGACAT	AAGACAAGGA	CCAAAGGAAC	CCTTTAGAGA	1680
CTATGTAGAC	CGGTTCTATA	AAACTCTAAG	AGCCGAGCAA	GCTTCACAGG	AGGTAAAAAA	1740
CCGGACGACA	GAAACCTTGT	TGGTCCAAAA	TGCGAACCCA	GATTGTAAGA	CTATTTTAAA	1800
AGCATTGGGA	CCAGCAGCTA	CACTAGAAGA	AATGATGACA	GCATGTCAGG	GAGTGGGAGG	1860
ACCTGGTCAT	AAAGCAAGAG	TTTTGGCGGA	AGCGATGAGC	CAAGTAACAA	ATTCAGCTAC	1920

CATAATGATG CAGAGAGGCA ATTTTAGGAA TCAAAGAAAG ATTATCAAGT GCTTCAATTG 1980
TGGCAAAGAA GGGCACATAG CCAAAAATTG CAGGGCCCCT AGGAAAAGGG GCTGTTGGAA 2040
ATGTGGAAAG GAAGGACACC AAATGAAAGA TTGTACTGAG AGACAGGCTA ATTTTTTAGG 2100
GAAGATCTGG CCTTCCTGCA AGGGAAGGCG GAATTTTCCT CAGAGCAGAA CAGAGCCAAC 2160
AGCCCCACCA GAAGAGAGCT TCAGGTTTGG GGAAGAGACA ACAACTCCCT ATCAGAAGCA 2220
GGAGAAGAAG CAGGAGACGA TAGACAAGGA CCTGTATCCT TTAGCTTCCC TCAAATCACT 2280
CTTTGGCAAC GACCCATTGT CACAATAAAG ATAGGGGGGC AACTAAAGGA AGCTCTATTA 2340
GATACAGGAG CAGATGATAC AGTATTAGGA GAAATGAATT TGCCAAGAAG ATGGAAACCA 2400
AAAATGATAG GGGGAATTGG AGGTTTTATC AAAGTAAGAC AGTATGATCA GATAACCATA 2460
GGAATCTGTG GACATAAAGC TATAGGTACA GTATTAGTAG GACCTACACC TGTCAACATA 2520
ATTGGAAGAA ATCTGTTGAC TCAGCTTGGG TGCAC TTAA ATTTTCCCAT TAGTCCTATT 2580
GAAACTGTAC CAGTAAAATT AAAGCCAGGA ATGGATGGCC CAAAAGTTAA ACAATGGCCA 2640
TTGACAGAAG AAAAAATAAA AGCATTATA GAAATTTGTA CAGAAATGGA AAAGGAAGGG 2700
AAAATTTCAA AAATTGGGCC TGAAAATCCA TACAATACTC CAGTATTTGC CATAAAGAAA 2760
AAAGACAGTA CTAAATGGAG AAAATTAGTA GATTCAGAG AACTTAATAA GAAACTCAA 2820
GACTTCTGGG AAGTTCAATT AGGAATACCA CATCCTGCAG GGTAAAAAA GAAAAAATCA 2880
GTAACAGTAC TGGATGTGGG TGATGCATAT TTTTCAGTTC CCTTAGATAA AGACTTCAGG 2940
AAGTATACTG CATTTACCAT ACCTAGTATA AACAATGAAA CACCAGGGAT TAGATATCAG 3000
TACAATGTGC TTCCACAGGG ATGGAAAGGA TCACCAGCAA TATCCAAAG TAGCATGACA 3060
AAAATCTTAG AGCCTTTTAG AAAACAAAAT CCAGACATAG TTATCTATCA ATACATGGAT 3120
GATTTGTATG TAGGATCTGA CTTAGAAATA GGGCAGCATA GAGCAAAAAT AGAGGAACTG 3180
AGACGACATC TGTTGAGGTG GGGATTTACC ACACCAGACA AAAACATCA GAAAGAACCT 3240
CCATTCCTTT GGATGGGTTA TGAAC TCCAT CCTGATAAAT GGACAGTACA GCCTATAGTG 3300
CTACCAGAAA AAGACAGCTG GACTGTCAAT GACATACAGA AGTTAGTGGG AAAATTGAAT 3360
TGGGCAAGTC AGATTTACGC AGGGATTAAA GTAAAGCAAT TATGTAACT CCTTAGAGGA 3420
ACCAAAGCAC TAACAGAAGT AATACCACTA ACAGAAGAAG CAGAGCTAGA ACTGGCAGAA 3480
AACAGGGAAA TTCTAAAAGA ACCAGTACAT GGAGTGTATT ATGACCCATC AAAAGACTTA 3540
ATAGCAGAAG TACAGAAGCA GGGGCAAGGC CAATGGACAT ATCAAATTTA TCAAGAGCCA 3600
TTTAAAAATC TGAAAACAGG CAAATATGCA AGAATGAGGG GTGCCCACAC TAATGATGTA 3660
AAACAATTAA CAGAGGCAGT GCAAAAAATA GCCACAGAAA GCATAGTAAT ATGGGGAAAG 3720
ACTCCTAAAT TTAGACTACC CATACAAAA GAAACATGGG AACATGGTG GACAGAGTAT 3780
ACGTAAGCCA CCTGGATTCC TGAGTGGGAG GTTGTCAATA CCCCTCCCTT AGTGAAATTA 3840
TGGTACCAGT TAGAGAAAGA ACCCATAGTA GGTGCAGAAA CTTTCTATGT AGATGGGGCA 3900
GCTAACAGGG AGACTAAAA AGGAAAAGCA GGATATGTTA CTAACAGAGG AAGACAAAAG 3960

GTTGTCTCCC TAACTGACAC AACAAATCAG AAGACTGAGT TACAAGCAAT TCATCTAGCT 4020
TTGCAAGATT CAGGGTTAGA AGTAAACATA GTAACAGACT CACAATATGC ATTAGGAATC 4080
ATTCAAGCAC AACCAGATAA AAGTGAATCA GAGTTAGTCA GTCAAATAAT AGAGCAGTTA 4140
ATAAAAAAGG AAAAGGTCTA TCTGGCATGG GTACCAGCAC ACAAAGGAAT TGGAGGAAAT 4200
GAACAAGTAG ATAAATTAGT CAGTGCTGGA ATCAGGAAAG TACTATTTTT AGATGGAATA 4260
GATAAGGCCC AAGAAGACCA TGAGAAATAT CACAGTAATT GGAGAGCAAT GGCTAGTGAC 4320
TTTAACCTAC CACCTATAGT AGCAAAAGAA ATAGTAGCCA GCTGTGATAA ATGTCAGCTA 4380
AAAGGAGAAG CCATGCATGG ACAAGTAGAC TGTAGTCCAG GAATATGGCA ACTAGATTGT 4440
ACACATTTAG AAGGAAAAGT TATCCTGGTA GCAGTTCATG TAGCCAGTGG ATACATAGAA 4500
GCAGAAGTTA TTCCAGCAGA GACAGGGCAG GAGACAGCAT ACTTTCTCTT AAAATTAGCA 4560
GGAAGATGGC CAGTAAAAAC AATACATACA GACAATGGCC CCAATTTTAC CAGTACTACG 4620
GTTAAGGCCG CCTGTTGGTG GACGGGAATC AAGCAGGAAT TTGGCATTCC CTACAATCCC 4680
CAAAGTCAAG GAGTAATAGA ATCTATGAAT AAAGAATTAA AGAAAATTAT AGGACAGGTA 4740
AGAGATCAGG CTGAACATCT TAAGAGAGCA GTACAAATGG CAGTATTCAT CCACAATTTT 4800
AAAAGAAAAG GGGGGATTGG GGGGTACAGT GCAGGGGAAA GAATAGTAGG CATAATAGCA 4860
ACAGACATAC AAATAAAGA ACTACAAAAA CAAATTACAA AAATTCAAAA TTTTCGGGTT 4920
TATTACAGGG ACAGCAGAGA TCCACTTTGG AAAGGACCAG CAAAGCTTCT CTGGAAAGGT 4980
GAAGGGGCAG TAGTAATACA AGATAATAAT GACATAAAAG TAGTGCCAAG AAGAAAAGCA 5040
AAGGTCATTA GGGATTATGG AAAACAGACG GCAGGTGATG ATTGTGTGGC AAGCAGACAG 5100
GATGAGGATT AGAACATGGA AAAGTTTAGT AAAACACCAT ATGTATATTT CAAAGAAAGC 5160
TAAAGGACGG TTTTATAGAC ATCACTATGA AAGCACTCAT CCAAGAATAA GTTCAGAAGT 5220
ACACATCCCA CTAGGGGATG CTAGATTGGT AATAACAACA TATTGGGGTC TGCATACAGG 5280
AGAAAGAGAC TGGCATTTAG GTCAGGGAGT CTCCATAGAA TGGAGGAAAA AGAGATATAG 5340
CACACAAGTA GACCCTGACC TAGCAGACCA CCTAATTCAT CTGCATTACT TTGATTGTTT 5400
TTCAGACTCT GCCATAAGAA AGGCCATATT AGGACATAGA GTTAGTCCTA TTTGTGAATT 5460
TCAAGCAGGA CATAACAAGG TAGGACCTCT ACAGTACTTG GCACTAACAG CATTAATAAC 5520
ACCAAAAAAG ATAAAGCCAC CTTTGCCTAG TGTTAAGAAA CTGACAGAGG ATAGATGGAA 5580
CAAGCCCCAG AAGACCAAGG GCCACAGAGG GAGCCATACA ATCAATGGGC ACTAGAGCTT 5640
TTAGAGGAGC TTAAGAATGA AGCTGTTAGA CATTTTCCTA GGATATGGCT CCATGGCTTA 5700
GGGCAACATA TCTATGAAAC TTATGGGGAT ACTTGGGCAG GAGTGGAAGC CATAATAAGA 5760
ATTCTACAAC AACTGCTGTT TATTCATTTT AGAATTGGGT GTCGACATAG CAGAATAGGC 5820
ATTATTCGAC AGAGGAGAGC AAGAAATGGA GCCAGTAGAT CCTAGACTAG AGCCCTGGAA 5880
GCATCCAGGA AGTCAGCCTA AGACTGCTTG TACCACTTGC TATTGTAAAA AGTGTTGCTT 5940

TCATTGCCAA GTTTGTTTCA CAAAAAAGC CTTAGGCATC TCCTATGGCA GGAAGAAGCG 6000
 GAGACAGCGA CGAAGAGCTC CTGAAGACAG TCAGACTCAT CAAGTTTCTC TACCAAAGCA 6060
 GTAAGTAGTA CATGTAATGC AACCTTTAGT AATAGCAGCA ATAGTAGCAT TAGTAGTAGC 6120
 AGGAATAATA GCAATAGTTG TGTGATCCAT AGTATTCATA GAATATAGGA AAATAAGAAG 6180
 ACAAAGAAAA ATAGACAGGT TAATTGATAG AATAAGCGAA AGAGCAGAAG ACAGTGGCA 6239
 ATG AGA GTG AAG GGG ATC AGG AGG AAT TAT CAG CAC TGG TGG GGA TGG 6287
 Met Arg Val Lys Gly Ile Arg Arg Asn Tyr Gln His Trp Trp Gly Trp
 1 5 10 15
 GGC ACG ATG CTC CTT GGG TTA TTA ATG ATC TGT AGT GCT ACA GAA AAA 6335
 Gly Thr Met Leu Leu Gly Leu Leu Met Ile Cys Ser Ala Thr Glu Lys
 20 25 30
 TTG TGG GTC ACA GTC TAT TAT GGG GTA CCT GTG TGG AAA GAA GCA ACC 6383
 Leu Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp Lys Glu Ala Thr
 35 40 45
 ACC ACT CTA TTT TGT GCA TCA GAT GCT AAA GCA TAT GAT ACA GAG GTA 6431
 Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Asp Thr Glu Val
 50 55 60
 CAT AAT GTT TGG GCC ACA CAA GCC TGT GTA CCC ACA GAC CCC AAC CCA 6479
 His Asn Val Trp Ala Thr Gln Ala Cys Val Pro Thr Asp Pro Asn Pro
 65 70 75 80
 CAA GAA GTA GAA TTG GTA AAT GTG ACA GAA AAT TTT AAC ATG TGG AAA 6527
 Gln Glu Val Glu Leu Val Asn Val Thr Glu Asn Phe Asn Met Trp Lys
 85 90 95
 AAT AAC ATG GTA GAA CAG ATG CAT GAG GAT ATA ATC AGT TTA TGG GAT 6575
 Asn Asn Met Val Glu Gln Met His Glu Asp Ile Ile Ser Leu Trp Asp
 100 105 110
 CAA AGC CTA AAG CCA TGT GTA AAA TTA ACC CCA CTC TGT GTT ACT TTA 6623
 Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu Cys Val Thr Leu
 115 120 125
 AAT TGC ACT GAT TTG AGG AAT ACT ACT AAT ACC AAT AAT AGT ACT GCT 6671
 Asn Cys Thr Asp Leu Arg Asn Thr Thr Asn Thr Asn Asn Ser Thr Ala
 130 135 140
 AAT AAC AAT AGT AAT AGC GAG GGA ACA ATA AAG GGA GGA GAA ATG AAA 6719
 Asn Asn Asn Ser Asn Ser Glu Gly Thr Ile Lys Gly Gly Glu Met Lys
 145 150 155 160
 AAC TGC TCT TTC AAT ATC ACC ACA AGC ATA AGA GAT AAG ATG CAG AAA 6767
 Asn Cys Ser Phe Asn Ile Thr Thr Ser Ile Arg Asp Lys Met Gln Lys
 165 170 175
 GAA TAT GCA CTT CTT TAT AAA CTT GAT ATA GTA TCA ATA GAT AAT GAT 6815
 Glu Tyr Ala Leu Leu Tyr Lys Leu Asp Ile Val Ser Ile Asp Asn Asp
 180 185 190
 AGT ACC AGC TAT AGG TTG ATA AGT TGT AAT ACC TCA GTC ATT ACA CAA 6863
 Ser Thr Ser Tyr Arg Leu Ile Ser Cys Asn Thr Ser Val Ile Thr Gln
 195 200 205
 GCT TGT CCA AAG ATA TCC TTT GAG CCA ATT CCC ATA CAC TAT TGT GCC 6911
 Ala Cys Pro Lys Ile Ser Phe Glu Pro Ile Pro Ile His Tyr Cys Ala
 210 215 220

CCG GCT GGT TTT GCG ATT CTA AAA TGT AAC GAT AAA AAG TTC AGT GGA Pro Ala Gly Phe Ala Ile Leu Lys Cys Asn Asp Lys Lys Phe Ser Gly 225 230 235 240	6959
AAA GGA TCA TGT AAA AAT GTC AGC ACA GTA CAA TGT ACA CAT GGA ATT Lys Gly Ser Cys Lys Asn Val Ser Thr Val Gln Cys Thr His Gly Ile 245 250 255	7007
AGG CCA GTA GTA TCA ACT CAA CTG CTG TTA AAT GGC AGT CTA GCA GAA Arg Pro Val Val Ser Thr Gln Leu Leu Leu Asn Gly Ser Leu Ala Glu 260 265 270	7055
GAA GAG GTA GTA ATT AGA TCT GAG AAT TTC ACT GAT AAT GCT AAA ACC Glu Glu Val Val Ile Arg Ser Glu Asn Phe Thr Asp Asn Ala Lys Thr 275 280 285	7103
ATC ATA GTA CAT CTG AAT GAA TCT GTA CAA ATT AAT TGT ACA AGA CCC Ile Ile Val His Leu Asn Glu Ser Val Gln Ile Asn Cys Thr Arg Pro 290 295 300	7151
AAC TAC AAT AAA AGA AAA AGG ATA CAT ATA GGA CCA GGG AGA GCA TTT Asn Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe 305 310 315 320	7199
TAT ACA ACA AAA AAT ATA ATA GGA ACT ATA AGA CAA GCA CAT TGT AAC Tyr Thr Thr Lys Asn Ile Ile Gly Thr Ile Arg Gln Ala His Cys Asn 325 330 335	7247
ATT AGT AGA GCA AAA TGG AAT GAC ACT TTA AGA CAG ATA GTT AGC AAA Ile Ser Arg Ala Lys Trp Asn Asp Thr Leu Arg Gln Ile Val Ser Lys 340 345 350	7295
TTA AAA GAA CAA TTT AAG AAT AAA ACA ATA GTC TTT AAT CAA TCC TCA Leu Lys Glu Gln Phe Lys Asn Lys Thr Ile Val Phe Asn Gln Ser Ser 355 360 365	7343
GGA GGG GAC CCA GAA ATT GTA ATG CAC AGT TTT AAT TGT GGA GGG GAA Gly Gly Asp Pro Glu Ile Val Met His Ser Phe Asn Cys Gly Gly Glu 370 375 380	7391
TTT TTC TAC TGT AAT ACA TCA CCA CTG TTT AAT AGT ACT TGG AAT GGT Phe Phe Tyr Cys Asn Thr Ser Pro Leu Phe Asn Ser Thr Trp Asn Gly 385 390 395 400	7439
AAT AAT ACT TGG AAT AAT ACT ACA GGG TCA AAT AAC AAT ATC ACA CTT Asn Asn Thr Trp Asn Asn Thr Thr Gly Ser Asn Asn Asn Ile Thr Leu 405 410 415	7487
CAA TGC AAA ATA AAA CAA ATT ATA AAC ATG TGG CAG GAA GTA GGA AAA Gln Cys Lys Ile Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys 420 425 430	7535
GCA ATG TAT GCC CCT CCC ATT GAA GGA CAA ATT AGA TGT TCA TCA AAT Ala Met Tyr Ala Pro Pro Ile Glu Gly Gln Ile Arg Cys Ser Ser Asn 435 440 445	7583
ATT ACA GGG CTA CTA TTA ACA AGA GAT GGT GGT AAG GAC ACG GAC ACG Ile Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly Lys Asp Thr Asp Thr 450 455 460	7631
AAC GAC ACC GAG ATC TTC AGA CCT GGA GGA GGA GAT ATG AGG GAC AAT Asn Asp Thr Glu Ile Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn 465 470 475 480	7679

2093427

16

TGG	AGA	AGT	GAA	TTA	TAT	AAA	TAT	AAA	GTA	GTA	ACA	ATT	GAA	CCA	TTA	7727
Trp	Arg	Ser	Glu	Leu	Tyr	Lys	Tyr	Lys	Val	Val	Thr	Ile	Glu	Pro	Leu	
				485					490					495		
GGA	GTA	GCA	CCC	ACC	AAG	GCA	AAG	AGA	AGA	GTG	GTG	CAG	AGA	GAA	AAA	7775
Gly	Val	Ala	Pro	Thr	Lys	Ala	Lys	Arg	Arg	Val	Val	Gln	Arg	Glu	Lys	
			500					505					510			
AGA	GCA	GCG	ATA	GGA	GCT	CTG	TTC	CTT	GGG	TTC	TTA	GGA	GCA	GCA	GGA	7823
Arg	Ala	Ala	Ile	Gly	Ala	Leu	Phe	Leu	Gly	Phe	Leu	Gly	Ala	Ala	Gly	
		515					520					525				
AGC	ACT	ATG	GGC	GCA	GCG	TCA	GTG	ACG	CTG	ACG	GTA	CAG	GCC	AGA	CTA	7871
Ser	Thr	Met	Gly	Ala	Ala	Ser	Val	Thr	Leu	Thr	Val	Gln	Ala	Arg	Leu	
	530					535					540					
TTA	TTG	TCT	GGT	ATA	GTG	CAA	CAG	CAG	AAC	AAT	TTG	CTG	AGG	GCC	ATT	7919
Leu	Leu	Ser	Gly	Ile	Val	Gln	Gln	Gln	Asn	Asn	Leu	Leu	Arg	Ala	Ile	
545					550				555						560	
GAG	GCG	CAA	CAG	CAT	ATG	TTG	CAA	CTC	ACA	GTC	TGG	GGC	ATC	AAG	CAG	7967
Glu	Ala	Gln	Gln	His	Met	Leu	Gln	Leu	Thr	Val	Trp	Gly	Ile	Lys	Gln	
				565					570					575		
CTC	CAG	GCA	AGA	GTC	CTG	GCT	GTG	GAA	AGA	TAC	CTA	AAG	GAT	CAA	CAG	8015
Leu	Gln	Ala	Arg	Val	Leu	Ala	Val	Glu	Arg	Tyr	Leu	Lys	Asp	Gln	Gln	
			580					585					590			
CTC	CTG	GGG	TTT	TGG	GGT	TGC	TCT	GGA	AAA	CTC	ATT	TGC	ACC	ACT	ACT	8063
Leu	Leu	Gly	Phe	Trp	Gly	Cys	Ser	Gly	Lys	Leu	Ile	Cys	Thr	Thr	Thr	
		595				600						605				
GTG	CCT	TGG	AAT	GCT	AGT	TGG	AGT	AAT	AAA	TCT	CTG	GAT	GAT	ATT	TGG	8111
Val	Pro	Trp	Asn	Ala	Ser	Trp	Ser	Asn	Lys	Ser	Leu	Asp	Asp	Ile	Trp	
	610					615					620					
AAT	AAC	ATG	ACC	TGG	ATG	CAG	TGG	GAA	AGA	GAA	ATT	GAC	AAT	TAC	ACA	8159
Asn	Asn	Met	Thr	Trp	Met	Gln	Trp	Glu	Arg	Glu	Ile	Asp	Asn	Tyr	Thr	
625					630					635					640	
AGC	TTA	ATA	TAC	TCA	TTA	CTA	GAA	AAA	TCG	CAA	ACC	CAA	CAA	GAA	AAG	8207
Ser	Leu	Ile	Tyr	Ser	Leu	Leu	Glu	Lys	Ser	Gln	Thr	Gln	Gln	Glu	Lys	
				645					650					655		
AAT	GAA	CAA	GAA	TTA	TTG	GAA	TTG	GAT	AAA	TGG	GCA	AGT	TTG	TGG	AAT	8255
Asn	Glu	Gln	Glu	Leu	Leu	Glu	Leu	Asp	Lys	Trp	Ala	Ser	Leu	Trp	Asn	
			660					665					670			
TGG	TTT	GAC	ATA	ACA	AAT	TGG	CTG	TGG	TAT	ATA	AAA	ATA	TTC	ATA	ATG	8303
Trp	Phe	Asp	Ile	Thr	Asn	Trp	Leu	Trp	Tyr	Ile	Lys	Ile	Phe	Ile	Met	
		675					680					685				
ATA	GTA	GGA	GGC	TTG	GTA	GGT	TTA	AGA	ATA	GTT	TTT	GCT	GTA	CTT	TCT	8351
Ile	Val	Gly	Gly	Leu	Val	Gly	Leu	Arg	Ile	Val	Phe	Ala	Val	Leu	Ser	
	690					695					700					
ATA	GTG	AAT	AGA	GTT	AGG	CAG	GGA	TAC	TCA	CCA	TTG	TCG	TTG	CAG	ACC	8399
Ile	Val	Asn	Arg	Val	Arg	Gln	Gly	Tyr	Ser	Pro	Leu	Ser	Leu	Gln	Thr	
705					710					715					720	
CGC	CCC	CCA	GTT	CCG	AGG	GGA	CCC	GAC	AGG	CCC	GAA	GGA	ATC	GAA	GAA	8447
Arg	Pro	Pro	Val	Pro	Arg	Gly	Pro	Asp	Arg	Pro	Glu	Gly	Ile	Glu	Glu	
				725					730					735		

GAA GGT GGA GAG AGA GAC AGA GAC ACA TCC GGT CGA TTA GTG CAT GGA 8495
 Glu Gly Gly Glu Arg Asp Arg Asp Thr Ser Gly Arg Leu Val His Gly
 740 745 750

TTC TTA GCA ATT ATC TGG GTC GAC CTG CGG AGC CTG TTC CTC TTC AGC 8543
 Phe Leu Ala Ile Ile Trp Val Asp Leu Arg Ser Leu Phe Leu Phe Ser
 755 760 765

TAC CAC CAC AGA GAC TTA CTC TTG ATT GCA GCG AGG ATT GTG GAA CTT 8591
 Tyr His His Arg Asp Leu Leu Leu Ile Ala Ala Arg Ile Val Glu Leu
 770 775 780

CTG GGA CGC AGG GGG TGG GAA GTC CTC AAA TAT TGG TGG AAT CTC CTA 8639
 Leu Gly Arg Arg Gly Trp Glu Val Leu Lys Tyr Trp Trp Asn Leu Leu
 785 790 795 800

CAG TAT TGG AGT CAG GAA CTA AAG AGT AGT GCT GTT AGC TTG CTT AAT 8687
 Gln Tyr Trp Ser Gln Glu Leu Lys Ser Ser Ala Val Ser Leu Leu Asn
 805 810 815

GCC ACA GCT ATA GCA GTA GCT GAG GGG ACA GAT AGG GTT ATA GAA GTA 8735
 Ala Thr Ala Ile Ala Val Ala Glu Gly Thr Asp Arg Val Ile Glu Val
 820 825 830

CTG CAA AGA GCT GGT AGA GCT ATT CTC CAC ATA CCT ACA AGA ATA AGA 8783
 Leu Gln Arg Ala Gly Arg Ala Ile Leu His Ile Pro Thr Arg Ile Arg
 835 840 845

CAG GGC TTG GAA AGG GCT TTG CTA TAAGATGGGT GGCAAATGGT CAAAACGTGT 8837
 Gln Gly Leu Glu Arg Ala Leu Leu
 850 855

GACTGGATGG CCTACTGTAA GGGAAAGAAT GAGACGAGCT GAACCAGCTG AGCTAGCAGC 8897
 AGATGGGGTG GGAGCAGCAT CCCGAGACCT GGAAAAACAT GGAGCACTCA CAAGTAGCAA 8957
 TACAGCAGCT ACCAATGCTG ATTGTGCCTG GCTAGAAGCA CAAGAGGAGG AGGAAGTGGG 9017
 TTTTCCAGTC AAACCTCAGG TACCTTTAAG ACCAATGACT TACAAAGCAG CTTTAGATCT 9077
 TAGCCACTTT TTAAAAGAAA AGGGGGGACT GGATGGGTTA ATTTACTCCC AAAAGAGACA 9137
 AGACATCCTT GATCTGTGGG TCTACCACAC ACAAGGCTAC TTCCCTGATT GGCAGAACTA 9197
 CACACCAGGG CCAGGGATCA GATATCCACT GACCTTTGGA TGGTGCTTCA AGCTAGTACC 9257
 AGTTGAGCCA GAGAAGATAG AAGAGGCCAA TAAAGGAGAG AACAACCTGCT TGTTACACCC 9317
 TATGAGCCAG CATGGATGGA TGACCCGGAG AGAGAAGTGT TAGTGTGGAA GTCTGACAGC 9377
 CACCTAGCAT TTCAGCATTG TGCCCGAGAG CTGCATCCGG AGTACTACAA GAACTGCTGA 9437
 CATCGAGCTA TCTACAAGGG ACTTTCCGCT GGGGACTTTC CAGGGAGGTG TGGCCTGGGC 9497
 GGGACCGGGG AGTGGCGAGC CCTCAGATCG TGCATATAAG CAGCTGCTTT CTGCCTGTAC 9557
 TGGGTCTCTC TGGTTAGACC AGATCTGAGC CTGGGAGCTC TCTGGCTAAC TAGGGAACCC 9617
 ACTGCTTAAG CCTCAATAAA GCTTGCCTTG AGTGCTTCAA GTAGTGTGTG CCCGTCTGTT 9677
 ATGTGACTCT GGTAGCTAGA GATCCCTCAG ATCCTTTTAG GCAGTGTGGA AAATCTCTAG 9737
 CA 9739

WO 92/06990

18

PCT/US91/07611

TABLE IA

Met	Arg	Val	Lys	Gly	Ile	Arg	Arg	Asn	Tyr	Gln	His	Trp	Trp	Gly	Trp	1	5	10	15
Gly	Thr	Met	Leu	Leu	Gly	Leu	Leu	Met	Ile	Cys	Ser	Ala	Thr	Glu	Lys	20	25	30	
Leu	Trp	Val	Thr	Val	Tyr	Tyr	Gly	Val	Pro	Val	Trp	Lys	Glu	Ala	Thr	35	40	45	
Thr	Thr	Leu	Phe	Cys	Ala	Ser	Asp	Ala	Lys	Ala	Tyr	Asp	Thr	Glu	Val	50	55	60	
His	Asn	Val	Trp	Ala	Thr	Gln	Ala	Cys	Val	Pro	Thr	Asp	Pro	Asn	Pro	65	70	75	80
Gln	Glu	Val	Glu	Leu	Val	Asn	Val	Thr	Glu	Asn	Phe	Asn	Met	Trp	Lys	85	90	95	
Asn	Asn	Met	Val	Glu	Gln	Met	His	Glu	Asp	Ile	Ile	Ser	Leu	Trp	Asp	100	105	110	
Gln	Ser	Leu	Lys	Pro	Cys	Val	Lys	Leu	Thr	Pro	Leu	Cys	Val	Thr	Leu	115	120	125	
Asn	Cys	Thr	Asp	Leu	Arg	Asn	Thr	Thr	Asn	Thr	Asn	Asn	Ser	Thr	Ala	130	135	140	
Asn	Asn	Asn	Ser	Asn	Ser	Glu	Gly	Thr	Ile	Lys	Gly	Gly	Glu	Met	Lys	145	150	155	160
Asn	Cys	Ser	Phe	Asn	Ile	Thr	Thr	Ser	Ile	Arg	Asp	Lys	Met	Gln	Lys	165	170	175	
Glu	Tyr	Ala	Leu	Leu	Tyr	Lys	Leu	Asp	Ile	Val	Ser	Ile	Asp	Asn	Asp	180	185	190	
Ser	Thr	Ser	Tyr	Arg	Leu	Ile	Ser	Cys	Asn	Thr	Ser	Val	Ile	Thr	Gln	195	200	205	
Ala	Cys	Pro	Lys	Ile	Ser	Phe	Glu	Pro	Ile	Pro	Ile	His	Tyr	Cys	Ala	210	215	220	
Pro	Ala	Gly	Phe	Ala	Ile	Leu	Lys	Cys	Asn	Asp	Lys	Lys	Phe	Ser	Gly	225	230	235	240
Lys	Gly	Ser	Cys	Lys	Asn	Val	Ser	Thr	Val	Gln	Cys	Thr	His	Gly	Ile	245	250	255	
Arg	Pro	Val	Val	Ser	Thr	Gln	Leu	Leu	Leu	Asn	Gly	Ser	Leu	Ala	Glu	260	265	270	
Glu	Glu	Val	Val	Ile	Arg	Ser	Glu	Asn	Phe	Thr	Asp	Asn	Ala	Lys	Thr	275	280	285	
Ile	Ile	Val	His	Leu	Asn	Glu	Ser	Val	Gln	Ile	Asn	Cys	Thr	Arg	Pro	290	295	300	
Asn	Tyr	Asn	Lys	Arg	Lys	Arg	Ile	His	Ile	Gly	Pro	Gly	Arg	Ala	Phe	305	310	315	320
Tyr	Thr	Thr	Lys	Asn	Ile	Ile	Gly	Thr	Ile	Arg	Gln	Ala	His	Cys	Asn	325	330	335	
Ile	Ser	Arg	Ala	Lys	Trp	Asn	Asp	Thr	Leu	Arg	Gln	Ile	Val	Ser	Lys	340	345	350	
Leu	Lys	Glu	Gln	Phe	Lys	Asn	Lys	Thr	Ile	Val	Phe	Asn	Gln	Ser	Ser	355	360	365	

19

2093427

Gly Gly Asp Pro Glu Ile Val Met His Ser Phe Asn Cys Gly Gly Glu
 370 375 380
 Phe Phe Tyr Cys Asn Thr Ser Pro Leu Phe Asn Ser Thr Trp Asn Gly
 385 390 395 400
 Asn Asn Thr Trp Asn Asn Thr Thr Gly Ser Asn Asn Asn Ile Thr Leu
 405 410 415
 Gln Cys Lys Ile Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys
 420 425 430
 Ala Met Tyr Ala Pro Pro Ile Glu Gly Gln Ile Arg Cys Ser Ser Asn
 435 440 445
 Ile Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly Lys Asp Thr Asp Thr
 450 455 460
 Asn Asp Thr Glu Ile Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn
 465 470 475 480
 Trp Arg Ser Glu Leu Tyr Lys Tyr Lys Val Val Thr Ile Glu Pro Leu
 485 490 495
 Gly Val Ala Pro Thr Lys Ala Lys Arg Arg Val Val Gln Arg Glu Lys
 500 505 510
 Arg Ala Ala Ile Gly Ala Leu Phe Leu Gly Phe Leu Gly Ala Ala Gly
 515 520 525
 Ser Thr Met Gly Ala Ala Ser Val Thr Leu Thr Val Gln Ala Arg Leu
 530 535 540
 Leu Leu Ser Gly Ile Val Gln Gln Gln Asn Asn Leu Leu Arg Ala Ile
 545 550 555 560
 Glu Ala Gln Gln His Met Leu Gln Leu Thr Val Trp Gly Ile Lys Gln
 565 570 575
 Leu Gln Ala Arg Val Leu Ala Val Glu Arg Tyr Leu Lys Asp Gln Gln
 580 585 590
 Leu Leu Gly Phe Trp Gly Cys Ser Gly Lys Leu Ile Cys Thr Thr Thr
 595 600 605
 Val Pro Trp Asn Ala Ser Trp Ser Asn Lys Ser Leu Asp Asp Ile Trp
 610 615 620
 Asn Asn Met Thr Trp Met Gln Trp Glu Arg Glu Ile Asp Asn Tyr Thr
 625 630 635 640
 Ser Leu Ile Tyr Ser Leu Leu Glu Lys Ser Gln Thr Gln Gln Glu Lys
 645 650 655
 Asn Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn
 660 665 670
 Trp Phe Asp Ile Thr Asn Trp Leu Trp Tyr Ile Lys Ile Phe Ile Met
 675 680 685
 Ile Val Gly Gly Leu Val Gly Leu Arg Ile Val Phe Ala Val Leu Ser
 690 695 700
 Ile Val Asn Arg Val Arg Gln Gly Tyr Ser Pro Leu Ser Leu Gln Thr
 705 710 715 720

Arg Pro Pro Val Pro Arg Gly Pro Asp Arg Pro Glu Gly Ile Glu Glu
725 730 735

Glu Gly Gly Glu Arg Asp Arg Asp Thr Ser Gly Arg Leu Val His Gly
740 745 750

Phe Leu Ala Ile Ile Trp Val Asp Leu Arg Ser Leu Phe Leu Phe Ser
755 760 765

Tyr His His Arg Asp Leu Leu Leu Ile Ala Ala Arg Ile Val Glu Leu
770 775 780

Leu Gly Arg Arg Gly Trp Glu Val Leu Lys Tyr Trp Trp Asn Leu Leu
785 790 795 800

Gln Tyr Trp Ser Gln Glu Leu Lys Ser Ser Ala Val Ser Leu Leu Asn
805 810 815

Ala Thr Ala Ile Ala Val Ala Glu Gly Thr Asp Arg Val Ile Glu Val
820 825 830

Leu Gln Arg Ala Gly Arg Ala Ile Leu His Ile Pro Thr Arg Ile Arg
835 840 845

Gln Gly Leu Glu Arg Ala Leu Leu
850 855

TABLE II

TGGATGGGTT AATTTACTCC CAAAGAGACA AGACATCCTT GATCTGTGGG TCTACCACAC	60
ACAAGGCTAC TTCCCTGATT GGCAGAACTA CACACCAGGG CCAGGGATCA GATATCCACT	120
GACCTTTGGA TGGTGCTTCA AGCTAGTACC AGTTGAGCCA GAGAAGATAG AAGAGGCCAA	180
TAAAGGAGAG AACAACTGCT TGTTACACCC TATGAGCCAG CATGGGATGG ATGACCCGGA	240
GAGAGAAGTG TTAGTGTGGA AGTCTGACAG CCACCTAGCA TTTCAGCATT ATGCCCGAGA	300
GCTGCATCCG GAGTACTACA AGAACTGCTG ACATCGAGCT ATCTACAAGG GACTTTCCGC	360
TGGGGACTTT CCAGGGAGGT GTGGCCTGGG CGGGACCGGG GAGTGGCGAG CCCTCAGATG	420
CTGCATATAA GCAGCTGCTT TCTGCCTGTA CTGGGTCTCT CTGGTTAGAC CAGATCTGAG	480
CCTGGGAGCT CTCTGGCTAA CTAGGGAACC CACTGCTTAA GCCTCAATAA AGCTTGCCTT	540
GAGTGCTTCA AGTAGTGTGT GCCCGTCTGT TATGTGACTC TGGTAGCTAG AGATCCCTCA	600
GATCCTTTTA GGCAGTGTGG AAAATCTCTA GCAGTGGCGC CCGAACAGGG ACTTGAAAGC	660
GAAAGAGAAA CCAGAGGAGC TCTCTCGACG CAGGACTCGG CTTGCTGAAG CGCGCACGGC	720
AAGAGGCGAG GGGCGGCGAC TGGTGAGTAC GCCAAAATTC TTGACTAGCG GAGGCTAGAA	780
GGAGAGAGAT GGGTGCGAGA GCGTCGGTAT TAAGCGGGGG AGAATTAGAT CGATGGGAAA	840
AAATTCGGTT AAGGCCAGGG GGAAAGAAAA AATATAAATT AAAACATGTA GTATGGGCAA	900
GCAGGGAGCT AGAACGATTC GCAGTCAATC CTGGCCTGTT AGAAACATCA GAAGGCTGTA	960
GACAAATACT GGGACAGCTA CAACCATCCC TTCAGACAGG ATCAGAAGAA CTTAAATCAT	1020
TATATAATAC AGTAGCAACC CTCTATTGTG TGCATCAAAA GATAGAGATA AAAGACACCA	1080
AGGAAGCTTT AGAGAAAATA GAGGAAGAGC AAAACAAAAG TAAGAAAAAA GCACAGCAAG	1140
CAGTAGCTGA CACAGGAAAC AGAGGAAACA GCAGCCAAGT CAGCCAAAAT TACCCCATAG	1200
TGCAGAACAT CCAGGGGCAA ATGGTACATC AGGCCATATC ACCTAGAACT TTAAATGCAT	1260
GGGTAAAAGT AGTAGAAGAG AAGGCTTTCA GCCCAGAAGT AATACCCATG TTTTCAGCAT	1320
TATCAGAAGG AGCCACCCCA CAAGATTTAA ACACCATGCT AAACACAGTG GGGGGACATC	1380
AAGCAGCCAT GCAAATGTTA AAAGAGACCA TCAATGAGGA AGCTGCAGAA TGGGATAGAT	1440
TGCATCCAGT GCATGCAGGG CCTATTGCAC CAGGCCAGAT GAGAGAACCA AGGGGAAGTG	1500
ACATAGCAGG AACTACTAGT ACCCTTCAGG AACAAATAGG ATGGATGACA AATAATCCAC	1560
CTATCCCAGT AGGAGAAATC TATAAAAGAT GGATAATCCT GGGATTAAAT AAAATAGTAA	1620
GGATGTATAG CCCTTCCAGC ATTCTGGACA TAAGACAAGG ACCAAAGGAA CCCTTTAGAG	1680
ACTATGTAGA CCGGTTCTAT AAAACTCTAA GAGCCGAGCA AGCTTCACAG GAGGTAAAAA	1740
ATTGGATGAC AGAAACCTTG TTGGTCCAAA ATGCGAACCC AGATTGTAAG ACTATTTTAA	1800
AAGCATTGGG ACCAGCAGCT AACTAGAAG AAATGATGAC AGCATGTCAG GGAGTGGGAG	1860
GACCTGGTCA TAAAGCAAGA GTTTTGGCGG AAGCGATGAG CCAAGTAACA AATTCAGCTA	1920

2093427

22

CCATAATGAT GCAGAGAGGC AATTTTAGGA ATCAAAGAAA GATTATCAAG TGCTTCAATT 1980
GTGGCAAAGA AGGGCACATA GCCAAAAATT GCAGGGCCCC TAGGAAAAGG GGCTGTTGGA 2040
AATGTGGAAA GGAAGGACAC CAAATGAAAG ATTGTACTGA GAGACAGGCT AATTTTTTAG 2100
GGAAGATCTG GCCTTCCTGC AAGGGAAGGC AGGGAATTTT CCTCAGAGCA GAACAGAGCC 2160
AACAGCCCCA CCAGAAGAGA GCTTCAGGTT TGGGGAAGAG ACAACAACCTC CCTATCAGAA 2220
GCAGGAGAAG AAGCAGGAGA CGATAGACAA GGACCTGTAT CCTTTAGCTT CCCTCAAATC 2280
ACTCTTTGGC AACGACCCAT TGTCACAATA AAGATAGGGG GGCAACTAAA GGAAGCTCTA 2340
TTAGATACAG GAGCAGATGA TACAGTATTA GAAGAAATGA ATTTGCCAGG AAGATGGAAA 2400
CCAAAAATGA TAGGGGGAAT TGGAGGTTTT ATCAAAGTAA GACAGTATGA TCAGATAACC 2460
ATAGAAATCT GTGGACATAA AGCTATAGGT ACAGTATTAG TAGGACCTAC ACCTGTCAAC 2520
ATAATTGGAA GAAATCTGTT GACTCAGCTT GGGTGCACTT TAAATTTTCC CATTAGTCCT 2580
ATTGAAACTG TACCAGTAAA ATTAAAGCCA GGAATGGATG GCCCAAAGT TAAACAATGG 2640
CCATTGACAG AAGAAAAAAT AAAAGCATT AATAGAAATTT GTACAGAAAT GGAAAAGGAA 2700
GGGAAAATTT CAAAATTGG GCCTGAAAAT CCATACAATA CTCCAGTATT TGCCATAAAG 2760
AAAAAAGACA GTACTAAATG GAGAAAATTA GTAGATTTCA GAGAACTTAA TAAGAAAAC 2820
CAAGACTTCT GGAAGTTCA ATTAGGAATA CCACATCCTG CAGGGTTAAA AAAGAAAAAA 2880
TCAGTAACAG TACTGGATGT GGGTGATGCA TATTTTTCAG TTCCCTTAGA TAAAGACTTC 2940
AGGAAGTATA CTGCATTTAC CATACTAGT ATAAACAATG AAACACCAGG GATTAGATAT 3000
CAGTACAATG TGCTTCCACA GGGATGGAAA GGATCACCAG CAATATTCCA AAGTAGCATG 3060
ACAAAATCT TAGAGCCTTT TAGAAAACAA AATCCAGACA TAGTTATCTA TCAATACATG 3120
GATGATTTGT ATGTAGGATC TGACTTAGAA ATAGGGCAGC ATAGAGCAAA AATAGAGGAA 3180
CTGAGACGAC ATCTGTTGAG GTGGGGATTT ACCACACCAG ACAAAAAACA TCAGAAAGAA 3240
CCTCCATTCC TTTGGATGGG TTATGAACTC CATCCTGATA AATGGACAGT ACAGCCTATA 3300
GTGCTGCCAG AAAAAGACAG CTGGACTGTC AATGACATAC AGAAGTTAGT GGGAAAATTG 3360
AATTGGGCAA GTCAAATTTA CGCAGGGATT AAAGTAAAGC AATTATGTAA ACTCCTTAGA 3420
GGAACCAAAG CACTAACAGA AGTAATACCA CTAACAGAAG AAGCAGAGCT AGAACTGGCA 3480
GAAAACAGGG AAATTCTAAA AGAACCAGTA CATGGAGTGT ATTATGACCC ATCAAAGAC 3540
TTAATAGCAG AAGTACAGAA GCAGGGGCAA GGCCAATGGA CATATCAAAT TTATCAAGAG 3600
CCATTTAAAA ATCTGAAAAC AGGCAAATAT GCAAGAATGA GGGGTGCCCA CACTAATGAT 3660
GTAAAACAAT TAACAGAGGC AGTGCAAAAA ATAGCCACAG AAAGCATAGT AATATGGGGA 3720
AAGACTCCTA AATTTAGACT ACCCATACAA AAAGAAACAT GGGAAACATG GTGGACAGAG 3780
TATTGGCAAG CCACCTGGAT TCCTGAGTGG GAGTTTGTCA ATACCCCTCC CTTAGTGAAA 3840
TTATGGTACC AGTTAGAGAA AGAACCATA GTAGGAGCAG AAACCTTCTA TGTAGATGGG 3900
GCAGCTAACA GGGAGACTAA AAAAGGAAAA GCAGGATATG TTACTAACAG AGGAAGACAA 3960

AAGGTTGTCT CCCTAACTGA CACAACAAAT CAGAAGACTG AGTTACAAGC AATTCATCTA 4020
GCTTTGCAAG ATTCAGGGTT AGAAGTAAAC ATAGTAACAG ACTCACAATA TGCATTAGGA 4080
ATCATTCAAG CACAACCAGA TAAAAGTGAA TCAGAGTTAG TCAGTCAAAT AATAGAGCAG 4140
TTAATAAAAA AGGAAAAGGT CTATCTGGCA TGGGTACCAG CACACAAAGG AATTGGAGGA 4200
AATGAACAAG TAGATAAATT AGTCAGTGCT GGAATCAGGA AAGTACTATT TTTAGATGGA 4260
ATAGATAAGG CCCAAGAAGA CCATGAGAAA TATCACAGTA ATTGGAGAGC AATGGCTAGT 4320
GACTTTAACC TACCACCTAT AGTAGCAAAA GAAATAGTAG CCAGCTGTGA TAAATGTCAG 4380
CTAAAAGGAG AAGCCATGCA TGGACAAGTA GACTGTAGTC CAGGAATATG GCAACTAGAT 4440
TGTACACATT TAGAAGGAAA AGTTATCCTG GTAGCAGTTC ATGTAGCCAG TGGATACATA 4500
GAAGCAGAAG TTATTCCAGC AGAGACAGGG CAGGAGACAG CATACTTTCT CTTAAAATTA 4560
GCAGGAAGAT GGCCAGTAAA AACAATACAT ACAGACAATG GCCCCAATTT CACCAGTACT 4620
ACGGTTAAGG CCGCCTGTTG GTGGGCGGGG ATCAAGCAGG AATTGTCAT TCCCTACAAT 4680
CCCCAAAGTC AAGGAGTAAT AGAATCTATG AATAAAGAAT TAAAGAAAAT TATAGGACAG 4740
GTAAGAGATC AGGCTGAACA TCTTAAGACA GCAGTACAAA TGGCAGTATT CATCCACAAT 4800
TTTAAAAGAA AAGGGGGGAT TGGGGGGTAC AGTGCAGGGG AAAGAATAGT AGACATAATA 4860
GCAACAGACA TACAACTAA AGAACTACAA AAACAAATTA CAAAATTCA AAATTTTCGG 4920
GTTTATTACA GGGACAGCAG AGATCCACTT TGGAAAGGAC CAGCAAAGCT TCTCTGGAAA 4980
GGTGAAGGGG CAGTAGTAAT ACAAGATAAT AGTGACATAA AAGTAGTGCC AAGAAGAAAA 5040
GCAAAGATCA TTAGGGATTA TGGAAAACAG ATGGCAGGTG ATGATTGTGT GGCAAGTAGA 5100
CAGGATGAGG ATTAGAACAT GGAAAAGTTT AGTAAAACAC CATATGTATA TTTCAAAGAA 5160
AGCTAAAGGA TGGTTTTATA GACATCACTA TGAAAGCACT CATCCAAGAA TAAGTTCAGA 5220
AGTACACATC CCACTAGGGG ATGCTAGATT GGTAATAACA ACATATTGGG GTCTGCATAC 5280
AGGAGAAAGA GACTGGCATT TAGGTCAGGG AGTCTCCATA GAATGGAGGA AAAAGAGATA 5340
TAGCACACAA GTAGACCCTG ACCTAGCAGA CCACCTAATT CATCTGCATT ACTTTGATTG 5400
TTTTTCAGAC TCTGCCATAA GAAAGGCCAT ATTAGGACAT AGAGTTAGTC CTATTTGTGA 5460
ATTTCAAGCA GGACATAACA AGGTAGGATC TCTACAGTAC TTGGCACTAA CAGCATTAAAT 5520
AACACCAAAA AAGATAAAGC CACCTTTGCC TAGTGTTAAG AAAGTACAG AGGATAGATG 5580
GAACAAGCCC CAGAAGACCA AGGGCCACAG AGGGAGCCAT ACAATCAATG GGCATTAGAG 5640
CTTTTAGAGG AGCTTAAGAA TGAAGCTGTT AGACATTTTC CTAGGATATG GCTCCATGGC 5700
TTAGGGCAAC ATATCTATGA AACTTATGGG GATACTTGGG CAGGAGTGGA AGCCATAATA 5760
AGAATTCTAC AACAACTGCT GTTTATTCAT TTCAGAATTG GGTGTCGACA TAGCAGAATA 5820
GGCATTATTC GACAGAGGAG AGCAAGAAAT GGAGCCAGTA GATCCTAGAC TAGAGCCCTG 5880
GAAGCATCCA GGAAGTCAGC CTAAGACTGC TTGTACCACT TGCTATTGTA AAAAGTGTTG 5940

CTTTCATTGC CAAGTTTGTT TCACAAAAAA AGCCTTAGGC ATCTCCTATG GCAGGAAGAA 6000
 GCGGAGACAG CGACGAAGAG CTCCTGAAGA CAGTCAGACT CATCAAGTTT CTCTACCAAA 6060
 GCAGTAAGTA GTACATGTAA TGCAACCTTT AGTAATAGCA GCAATAGTAG CATTAGTAGT 6120
 AGCAGGAATA ATAGCAATAG TTGTGTGATC CATAGTATTC ATAGAATATA GGAAAATAAG 6180
 AAGACAAAGA AAAATAGACA GGGTAATTGA CAGAATAAGC GAAAGAGCAG AAGACAGTGG 6240
 CA ATG AGA GTG AAG GGG ATC AGG AGG AAT TAT CAG CAC TGG TGG GGA 6287
 Met Arg Val Lys Gly Ile Arg Arg Asn Tyr Gln His Trp Trp Gly
 1 5 10 15
 TGG GGC ACG ATG CTC CTT GGG TTA TTA ATG ATC TGT AGT GCT ACA GAA 6335
 Trp Gly Thr Met Leu Leu Gly Leu Leu Met Ile Cys Ser Ala Thr Glu
 20 25 30
 AAA TTG TGG GTC ACA GTC TAT TAT GGG GTA CCT GTG TGG AAA GAA GCA 6383
 Lys Leu Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp Lys Glu Ala
 35 40 45
 ACC ACC ACT CTA TTT TGT GCA TCA GAT GCT AAA GCA TAT GAT ACA GAG 6431
 Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Asp Thr Glu
 50 55 60
 GTA CAT AAT GTT TGG GCC ACA CAT GCC TGT GTA CCC ACA GAC CCC AAC 6479
 Val His Asn Val Trp Ala Thr His Ala Cys Val Pro Thr Asp Pro Asn
 65 70 75
 CCA CAA GAA GTA GAA TTG GTA AAT GTG ACA GAA AAT TTT AAC ATG TGG 6527
 Pro Gln Glu Val Glu Leu Val Asn Val Thr Glu Asn Phe Asn Met Trp
 80 85 90 95
 AAA AAT AAC ATG GTA GAA CAG ATG CAT GAG GAT ATA ATC AGT TTA TGG 6575
 Lys Asn Asn Met Val Glu Gln Met His Glu Asp Ile Ile Ser Leu Trp
 100 105 110
 GAT CAA AGC CTA AAG CCA TGT GTA AAA TTA ACC CCA CTC TGT GTT ACT 6623
 Asp Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu Cys Val Thr
 115 120 125
 TTA AAT TGC ACT GAT TTG AGG AAT ACT ACT AAT ACC AAT AAT AGT ACT 6671
 Leu Asn Cys Thr Asp Leu Arg Asn Thr Thr Asn Thr Asn Asn Ser Thr
 130 135 140
 GCT AAT AAC AAT AGT AAT AGC GAG GGA ACA ATA AAG GGA GGA GAA ATG 6719
 Ala Asn Asn Asn Ser Asn Ser Glu Gly Thr Ile Lys Gly Gly Glu Met
 145 150 155
 AAA AAC TGC TCT TTC AAT ATC ACC ACA AGC ATA AGA GAT AAG ATG CAG 6767
 Lys Asn Cys Ser Phe Asn Ile Thr Thr Ser Ile Arg Asp Lys Met Gln
 160 165 170 175
 AAA GAA TAT GCA CTT CTT TAT AAA CTT GAT ATA GTA TCA ATA AAT AAT 6815
 Lys Glu Tyr Ala Leu Leu Tyr Lys Leu Asp Ile Val Ser Ile Asn Asn
 180 185 190
 GAT AGT ACC AGC TAT AGG TTG ATA AGT TGT AAT ACC TCA GTC ATT ACA 6863
 Asp Ser Thr Ser Tyr Arg Leu Ile Ser Cys Asn Thr Ser Val Ile Thr
 195 200 205
 CAA GCT TGT CCA AAG ATA TCC TTT GAG CCA ATT CCC ATA CAC TAT TGT 6911
 Gln Ala Cys Pro Lys Ile Ser Phe Glu Pro Ile Pro Ile His Tyr Cys
 210 215 220

25 2093427

GCC CCG GCT GGT TTT GCG ATT CTA AAG TGT AAC GAT AAA AAG TTC AGT Ala Pro Ala Gly Phe Ala Ile Leu Lys Cys Asn Asp Lys Lys Phe Ser 225 230 235	6959
GGA AAA GGA TCA TGT AAA AAT GTC AGC ACA GTA CAA TGT ACA CAT GGA Gly Lys Gly Ser Cys Lys Asn Val Ser Thr Val Gln Cys Thr His Gly 240 245 250 255	7007
ATT AGG CCA GTA GTA TCA ACT CAA CTG CTG TTA AAT GGC AGT CTA GCA Ile Arg Pro Val Val Ser Thr Gln Leu Leu Leu Asn Gly Ser Leu Ala 260 265 270	7055
GAA GAA GAG GTA GTA ATT AGA TCT GAG AAT TTC AAT GAT AAT GCT AAA Glu Glu Glu Val Val Ile Arg Ser Glu Asn Phe Asn Asp Asn Ala Lys 275 280 285	7103
ACC ATC ATA GTA CAT CTG AAT GAA TCT GTA CAA ATT AAT TGT ACA AGA Thr Ile Ile Val His Leu Asn Glu Ser Val Gln Ile Asn Cys Thr Arg 290 295 300	7151
CCC AAC TAC AAT AAA AGA AAA AGG ATA CAT ATA GGA CCA GGG AGA GCA Pro Asn Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala 305 310 315	7199
TTT TAT ACA ACA AAA AAT ATA ATA GGA ACT ATA AGA CAA GCA CAT TGT Phe Tyr Thr Thr Lys Asn Ile Ile Gly Thr Ile Arg Gln Ala His Cys 320 325 330 335	7247
AAC ATT AGT AGA GCA AAA TGG AAT GAC ACT TTA AGA CAG ATA GTT AGC Asn Ile Ser Arg Ala Lys Trp Asn Asp Thr Leu Arg Gln Ile Val Ser 340 345 350	7295
AAA TTA AAA GAA CAA TTT AAG AAT AAA ACA ATA GTC TTT AAT CAA TCC Lys Leu Lys Glu Gln Phe Lys Asn Lys Thr Ile Val Phe Asn Gln Ser 355 360 365	7343
TCA GGA GGG GAC CCA GAA ATT GTA ATG CAC AGT TTT AAT TGT GGA GGG Ser Gly Gly Asp Pro Glu Ile Val Met His Ser Phe Asn Cys Gly Gly 370 375 380	7391
GAA TTT TTC TAC TGT AAT ACA TCA CCA CTG TTT AAT AGT ACT TGG AAT Glu Phe Phe Tyr Cys Asn Thr Ser Pro Leu Phe Asn Ser Thr Trp Asn 385 390 395	7439
GGT AAT AAT ACT TGG AAT AAT ACT ACA GGG TCA AAT AAC AAT ATC ACA Gly Asn Asn Thr Trp Asn Asn Thr Thr Gly Ser Asn Asn Asn Ile Thr 400 405 410 415	7487
CTT CAA TGC AAA ATA AAA CAA ATT ATA AAC ATG TGG CAG GAA GTA GGA Leu Gln Cys Lys Ile Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly 420 425 430	7535
AAA GCA ATA TAT GCC CCT CCC ATT GAA GGA CAA ATT AGA TGT TCA TCA Lys Ala Ile Tyr Ala Pro Pro Ile Glu Gly Gln Ile Arg Cys Ser Ser 435 440 445	7583
AAT ATT ACA GGG CTA CTA TTA ACA AGA GAT GGT GGT AAG GAC ACG GAC Asn Ile Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly Lys Asp Thr Asp 450 455 460	7631
ACG AAC GAC ACC GAG ATC TTC AGA CCT GGA GGA GGA GAT ATG AGG GAC Thr Asn Asp Thr Glu Ile Phe Arg Pro Gly Gly Gly Asp Met Arg Asp 465 470 475	7679

2093427

AAT TGG AGA AGT GAA TTA TAT AAA TAT AAA GTA GTA ACA ATT GAA CCA	7727
Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys Val Val Thr Ile Glu Pro	
480 485 490 495	
TTA GGA GTA GCA CCC ACC AAG GCA AAG AGA AGA GTG GTG CAG AGA GAA	7775
Leu Gly Val Ala Pro Thr Lys Ala Lys Arg Arg Val Val Gln Arg Glu	
500 505 510	
AAA AGA GCA GCG ATA GGA GCT CTG TTC CTT GGG TTC TTA GGA GCA GCA	7823
Lys Arg Ala Ala Ile Gly Ala Leu Phe Leu Gly Phe Leu Gly Ala Ala	
515 520 525	
GGA AGC ACT ATG GGC GCA GCG TCA GTG ACG CTG ACG GTA CAG GCC AGA	7871
Gly Ser Thr Met Gly Ala Ala Ser Val Thr Leu Thr Val Gln Ala Arg	
530 535 540	
CTA TTA TTG TCT GGT ATA GTG CAA CAG CAG AAC AAT TTG CTG AGG GCC	7919
Leu Leu Leu Ser Gly Ile Val Gln Gln Gln Asn Asn Leu Leu Arg Ala	
545 550 555	
ATT GAG GCG CAA CAG CAT ATG TTG CAA CTC ACA GTC TGG GGC ATC AAG	7967
Ile Glu Ala Gln Gln His Met Leu Gln Leu Thr Val Trp Gly Ile Lys	
560 565 570 575	
CAG CTC CAG GCA AGA ATC CTG GCT GTG GAA AGA TAC CTA AAG GAT CAA	8015
Gln Leu Gln Ala Arg Ile Leu Ala Val Glu Arg Tyr Leu Lys Asp Gln	
580 585 590	
CAG CTC CTG GGG ATT TGG GGT TGC TCT GGA AAA CTC ATT TGC ACC ACT	8063
Gln Leu Leu Gly Ile Trp Gly Cys Ser Gly Lys Leu Ile Cys Thr Thr	
595 600 605	
ACT GTG CCT TGG AAT GCT AGT TGG AGT AAT AAA TCT CTG GAT GAT ATT	8111
Thr Val Pro Trp Asn Ala Ser Trp Ser Asn Lys Ser Leu Asp Asp Ile	
610 615 620	
TGG AAT AAC ATG ACC TGG ATG CAG TGG GAA AGA GAA ATT GAC AAT TAC	8159
Trp Asn Asn Met Thr Trp Met Gln Trp Glu Arg Glu Ile Asp Asn Tyr	
625 630 635	
ACA AGC TTA ATA TAC TCA TTA CTA GAA AAA TCG CAA ACC CAA CAA GAA	8207
Thr Ser Leu Ile Tyr Ser Leu Leu Glu Lys Ser Gln Thr Gln Gln Glu	
640 645 650 655	
ATG AAT GAA CAA GAA TTA TTG GAA TTG GAT AAA TGG GCA AGT TTG TGG	8255
Met Asn Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp	
660 665 670	
AAT TGG TTT GAC ATA ACA AAT TGG CTG TGG TAT ATA AAA ATA TTC ATA	8303
Asn Trp Phe Asp Ile Thr Asn Trp Leu Trp Tyr Ile Lys Ile Phe Ile	
675 680 685	
ATG ATA GTA GGA GGC TTG GTA GGT TTA AGA ATA GTT TTT GCT GTA CTT	8351
Met Ile Val Gly Gly Leu Val Gly Leu Arg Ile Val Phe Ala Val Leu	
690 695 700	
TCT ATA GTG AAT AGA GTT AGG CAG GGA TAC TCA CCA TTG TCG TTG CAG	8399
Ser Ile Val Asn Arg Val Arg Gln Gly Tyr Ser Pro Leu Ser Leu Gln	
705 710 715	
ACC CGC CCC CCA GTT CCG AGG GGA CCC GAC AGG CCC GAA GGA ATC GAA	8447
Thr Arg Pro Pro Val Pro Arg Gly Pro Asp Arg Pro Glu Gly Ile Glu	
720 725 730 735	

GAA GAA GGT GGA GAG AGA GAC AGA GAC ACA TCC GGT CGA TTA GTG CAT	8495
Glu Glu Gly Gly Glu Arg Asp Arg Asp Thr Ser Gly Arg Leu Val His	
740 745 750	
GGA TTC TTA GCA ATT ATC TGG GTC GAC CTG CGG AGC CTG TTC CTC TTC	8543
Gly Phe Leu Ala Ile Ile Trp Val Asp Leu Arg Ser Leu Phe Leu Phe	
755 760 765	
AGC TAC CAC CAC TTG AGA GAC TTA CTC TTG ATT GCA GCG AGG ATT GTG	8591
Ser Tyr His His Leu Arg Asp Leu Leu Leu Ile Ala Ala Arg Ile Val	
770 775 780	
GAA CTT CTG GGA CGC AGG GGG TGG GAA GTC CTC AAA TAT TGG TGG AAT	8639
Glu Leu Leu Gly Arg Arg Gly Trp Glu Val Leu Lys Tyr Trp Trp Asn	
785 790 795	
CTC CTA CAG TAT TGG AGT CAG GAA CTA AAG AGT AGT GCT GTT AGC TTG	8687
Leu Leu Gln Tyr Trp Ser Gln Glu Leu Lys Ser Ser Ala Val Ser Leu	
800 805 810 815	
CTT AAT GCC ACA GAT ATA GCA GTA GCT GAG GGG ACA GAT AGG GTT ATA	8735
Leu Asn Ala Thr Asp Ile Ala Val Ala Glu Gly Thr Asp Arg Val Ile	
820 825 830	
GAA GTA CTG CAA AGA GCT GGT AGA GCT ATT CTC CAC ATA CCT ACA AGA	8783
Glu Val Leu Gln Arg Ala Gly Arg Ala Ile Leu His Ile Pro Thr Arg	
835 840 845	
ATA AGA CAG GGC TTG GAA AGG GCT TTG CTA TAAGATGGGT GGCAAATGGT	8833
Ile Arg Gln Gly Leu Glu Arg Ala Leu Leu	
850 855	
CAAAACGTGT GACTGGATGG CCTACTGTAA GGGAAAAAAT GAGACGAGCT GAACCAGCTG	8893
AGCCAGCAGC AGATGGGGTG GGAGCAGCAT CCCGAGACCT GGAAAAACAT GGAGCACTCA	8953
CAAGTAGCAA TACAGCAGCT ACCAATGCTG ATTGTGCCTG GCTAGAAGCA CAAGAGGAGG	9013
AGGAAGTGGG TTTTCCAGTC AGACCTCAGG TACCTTTAAG ACCAATGACT TACAAAGCAG	9073
CTTTAGATCT TAGCCACTTT TTAAGAGAAA AGGGGGGACT GGATGGGTTA ATTTACTCCC	9133
AAAAGAGACA AGACATCCTT GATCTGTGGG TCTACCACAC ACAAGGCTAC TTCCCTGATT	9193
GGCAGAACTA CACACCAGGG CCAGGGATCA GATATCCACT GACCTTTGGA TGGTGCTTCA	9253
AGCTAGTACC AGTTGAGCCA GAGAAGATAG AAGAGGCCAA TAAAGGAGAG AACAACTGCT	9313
TGTTACACCC TATGAGCCAG CATGGGATGG ATGACCCGGA GAGAGAAGTG TTAGTGTTGA	9373
AGTCTGACAG CCACCTAGCA TTTCAGCATT ATGCCCGAGA GCTGCATCCG GAGTACTACA	9433
AGAACTGCTG ACATCGAGCT ATCTACAAGG GACTTTCCGC TGGGGACTTT CCAGGGAGGT	9493
GTGGCCTGGG CGGGACCGGG GAGTGGCGAG CCCTCAGATG CTGCATATAA GCAGCTGCTT	9553
TCTGCCTGTA CTGGGTCTCT CTGGTTAGAC CAGATCTGAG CCTGGGAGCT CTCTGGCTAA	9613
CTAGGGAACC CACTGCTTAA GCCTCAATAA AGCTTGCCTT GAGTGCTTCA AGTAGTGTGT	9673
GCCCGTCTGT TATGTGACTC TGGTAGCTAG AGATCCCTCA GATCCTTTTA GGCAGTGTGG	9733
AAAATCTCTA GCA	9746

WO 92/06990

28
TABLE IIA

PCT/US91/07611

Met Arg Val Lys Gly Ile Arg Arg Asn Tyr Gln His Trp Trp Gly Trp
1 5 10 15

Gly Thr Met Leu Leu Gly Leu Leu Met Ile Cys Ser Ala Thr Glu Lys
20 25 30

Leu Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp Lys Glu Ala Thr
35 40 45

Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Asp Thr Glu Val
50 55 60

His Asn Val Trp Ala Thr His Ala Cys Val Pro Thr Asp Pro Asn Pro
65 70 75 80

Gln Glu Val Glu Leu Val Asn Val Thr Glu Asn Phe Asn Met Trp Lys
85 90 95

Asn Asn Met Val Glu Gln Met His Glu Asp Ile Ile Ser Leu Trp Asp
100 105 110

Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu Cys Val Thr Leu
115 120 125

Asn Cys Thr Asp Leu Arg Asn Thr Thr Asn Thr Asn Asn Ser Thr Ala
130 135 140

Asn Asn Asn Ser Asn Ser Glu Gly Thr Ile Lys Gly Gly Glu Met Lys
145 150 155 160

Asn Cys Ser Phe Asn Ile Thr Thr Ser Ile Arg Asp Lys Met Gln Lys
165 170 175

Glu Tyr Ala Leu Leu Tyr Lys Leu Asp Ile Val Ser Ile Asn Asn Asp
180 185 190

Ser Thr Ser Tyr Arg Leu Ile Ser Cys Asn Thr Ser Val Ile Thr Gln
195 200 205

Ala Cys Pro Lys Ile Ser Phe Glu Pro Ile Pro Ile His Tyr Cys Ala
210 215 220

Pro Ala Gly Phe Ala Ile Leu Lys Cys Asn Asp Lys Lys Phe Ser Gly
225 230 235 240

Lys Gly Ser Cys Lys Asn Val Ser Thr Val Gln Cys Thr His Gly Ile
245 250 255

Arg Pro Val Val Ser Thr Gln Leu Leu Leu Asn Gly Ser Leu Ala Glu
260 265 270

Glu Glu Val Val Ile Arg Ser Glu Asn Phe Asn Asp Asn Ala Lys Thr
275 280 285

Ile Ile Val His Leu Asn Glu Ser Val Gln Ile Asn Cys Thr Arg Pro
290 295 300

Asn Tyr Asn Lys Arg Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe
305 310 315 320

Tyr Thr Thr Lys Asn Ile Ile Gly Thr Ile Arg Gln Ala His Cys Asn
325 330 335

Ile Ser Arg Ala Lys Trp Asn Asp Thr Leu Arg Gln Ile Val Ser Lys
340 345 350

Leu Lys Glu Gln Phe Lys Asn Lys Thr Ile Val Phe Asn Gln Ser Ser
355 360 365

2093427

Gly Gly Asp Pro Glu Ile Val Met His Ser Phe Asn Cys Gly Gly Glu
 370 375 380
 Phe Phe Tyr Cys Asn Thr Ser Pro Leu Phe Asn Ser Thr Trp Asn Gly
 385 390 395 400
 Asn Asn Thr Trp Asn Asn Thr Thr Gly Ser Asn Asn Asn Ile Thr Leu
 405 410 415
 Gln Cys Lys Ile Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys
 420 425 430
 Ala Ile Tyr Ala Pro Pro Ile Glu Gly Gln Ile Arg Cys Ser Ser Asn
 435 440 445
 Ile Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly Lys Asp Thr Asp Thr
 450 455 460
 Asn Asp Thr Glu Ile Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn
 465 470 475 480
 Trp Arg Ser Glu Leu Tyr Lys Tyr Lys Val Val Thr Ile Glu Pro Leu
 485 490 495
 Gly Val Ala Pro Thr Lys Ala Lys Arg Arg Val Val Gln Arg Glu Lys
 500 505 510
 Arg Ala Ala Ile Gly Ala Leu Phe Leu Gly Phe Leu Gly Ala Ala Gly
 515 520 525
 Ser Thr Met Gly Ala Ala Ser Val Thr Leu Thr Val Gln Ala Arg Leu
 530 535 540
 Leu Leu Ser Gly Ile Val Gln Gln Gln Asn Asn Leu Leu Arg Ala Ile
 545 550 555 560
 Glu Ala Gln Gln His Met Leu Gln Leu Thr Val Trp Gly Ile Lys Gln
 565 570 575
 Leu Gln Ala Arg Ile Leu Ala Val Glu Arg Tyr Leu Lys Asp Gln Gln
 580 585 590
 Leu Leu Gly Ile Trp Gly Cys Ser Gly Lys Leu Ile Cys Thr Thr Thr
 595 600 605
 Val Pro Trp Asn Ala Ser Trp Ser Asn Lys Ser Leu Asp Asp Ile Trp
 610 615 620
 Asn Asn Met Thr Trp Met Gln Trp Glu Arg Glu Ile Asp Asn Tyr Thr
 625 630 635 640
 Ser Leu Ile Tyr Ser Leu Leu Glu Lys Ser Gln Thr Gln Gln Glu Met
 645 650 655
 Asn Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn
 660 665 670
 Trp Phe Asp Ile Thr Asn Trp Leu Trp Tyr Ile Lys Ile Phe Ile Met
 675 680 685
 Ile Val Gly Gly Leu Val Gly Leu Arg Ile Val Phe Ala Val Leu Ser
 690 695 700
 Ile Val Asn Arg Val Arg Gln Gly Tyr Ser Pro Leu Ser Leu Gln Thr
 705 710 715 720

30

Arg Pro Pro Val Pro Arg Gly Pro Asp Arg Pro Glu Gly Ile Glu Glu
725 730 735

Glu Gly Gly Glu Arg Asp Arg Asp Thr Ser Gly Arg Leu Val His Gly
740 745 750

Phe Leu Ala Ile Ile Trp Val Asp Leu Arg Ser Leu Phe Leu Phe Ser
755 760 765

Tyr His His Leu Arg Asp Leu Leu Leu Ile Ala Ala Arg Ile Val Glu
770 775 780

Leu Leu Gly Arg Arg Gly Trp Glu Val Leu Lys Tyr Trp Trp Asn Leu
785 790 795 800

Leu Gln Tyr Trp Ser Gln Glu Leu Lys Ser Ser Ala Val Ser Leu Leu
805 810 815

Asn Ala Thr Asp Ile Ala Val Ala Glu Gly Thr Asp Arg Val Ile Glu
820 825 830

Val Leu Gln Arg Ala Gly Arg Ala Ile Leu His Ile Pro Thr Arg Ile
835 840 845

Arg Gln Gly Leu Glu Arg Ala Leu Leu
850 855

TABLE III

GATCAAGGGC CACAGAGGGA GCCACACAAT GAATGGACAC TAGAGCTTTT AGAGGAGCTT	60
AAGAGTGAAG CTGTTAGACA CTTTCCTAGG ATATGGCTTC ATGGCTTAGG GCAACATATC	120
TATGAAACTT ATGGGGATAC TTGGGCAGGA GTGGAAGCCA TAATAAGAAT TCTGCAACAA	180
CTGCTGTTTA TCCATTTTCAG GATTGGGTGC CAACATAGCA GAATAGGTAT TATTCAACAG	240
AGGAGAGCAA GAAATGGAGC CAGTAGATCC TAAACTAGAG CCCTGGAAGC ATCCAGGAAG	300
TCAGCCTAAG ACTGCTTGTA CCACTTGCTA TTGTAAAAAG TGTGCTTTC ATTGCCAAGT	360
TTGCTTCATA ACAAAGGCT TAGGCATCTC CTATGGCAGG AAGAAGCGGA GACAGCGACG	420
AAGAGCTCCT CAAGACAGTG AGACTCATCA AGTTTCTCTA TCAAAGCAGT AAGTAGTACA	480
TGTAATGCAA GCTTTACAAA TATCAGCTAT AGTAGGATTA GTAGTAGCAG CAATAATAGC	540
AATAGTTGTG TGGACCATAG TATTCATAGA ATATAGGAAA ATATTAAGGC AAAGAAAAAT	600
AGACAGGTTA ATTGATAGAA TAACAGAAAG AGCAGAAGAC AGTGGCA ATG AGA GTG	656
Met Arg Val	
1	
ACG GAG ATC AGG AAG AGT TAT CAG CAC TGG TGG AGA TGG GGC ATC ATG	704
Thr Glu Ile Arg Lys Ser Tyr Gln His Trp Trp Arg Trp Gly Ile Met	
5 10 15	
CTC CTT GGG ATA TTA ATG ATC TGT AAT GCT GAA GAA AAA TTG TGG GTC	752
Leu Leu Gly Ile Leu Met Ile Cys Asn Ala Glu Glu Lys Leu Trp Val	
20 25 30 35	
ACA GTC TAT TAT GGG GTA CCT GTG TGG AAA GAA GCA ACC ACC ACT CTA	800
Thr Val Tyr Tyr Gly Val Pro Val Trp Lys Glu Ala Thr Thr Thr Leu	
40 45 50	
TTT TGT GCA TCA GAT CGT AAA GCA TAT GAT ACA GAG GTA CAT AAT GTT	848
Phe Cys Ala Ser Asp Arg Lys Ala Tyr Asp Thr Glu Val His Asn Val	
55 60 65	
TGG GCC ACA CAT GCC TGT GTA CCC ACA GAC CCC AAC CCA CAA GAA GTA	896
Trp Ala Thr His Ala Cys Val Pro Thr Asp Pro Asn Pro Gln Glu Val	
70 75 80	
GAA TTG AAA AAT GTG ACA GAA AAT TTT AAC ATG TGG AAA AAT AAC ATG	944
Glu Leu Lys Asn Val Thr Glu Asn Phe Asn Met Trp Lys Asn Asn Met	
85 90 95	
GTA GAA CAA ATG CAT GAG GAT ATA ATC AGT TTA TGG GAT CAA AGC CTA	992
Val Glu Gln Met His Glu Asp Ile Ile Ser Leu Trp Asp Gln Ser Leu	
100 105 110 115	
AAG CCA TGT GTA AAA TTA ACC CCA CTC TGT GTT ACT TTA AAT TGC ACT	1040
Lys Pro Cys Val Lys Leu Thr Pro Leu Cys Val Thr Leu Asn Cys Thr	
120 125 130	
GAT TTG AGG AAT GCT ACT AAT GGG AAT GAC ACT AAT ACC ACT AGT AGT	1088
Asp Leu Arg Asn Ala Thr Asn Gly Asn Asp Thr Asn Thr Thr Ser Ser	
135 140 145	

AGC	AGG	GGA	ATG	GTG	GGG	GGA	GGA	GAA	ATG	AAA	AAT	TGC	TCT	TTC	AAT	1136
Ser	Arg	Gly	Met	Val	Gly	Gly	Gly	Glu	Met	Lys	Asn	Cys	Ser	Phe	Asn	
		150					155					160				
ATC	ACC	ACA	AAC	ATA	AGA	GGT	AAG	GTG	CAG	AAA	GAA	TAT	GCA	CTT	TTT	1184
Ile	Thr	Thr	Asn	Ile	Arg	Gly	Lys	Val	Gln	Lys	Glu	Tyr	Ala	Leu	Phe	
		165				170					175					
TAT	AAA	CTT	GAT	ATA	GCA	CCA	ATA	GAT	AAT	AAT	AGT	AAT	AAT	AGA	TAT	1232
Tyr	Lys	Leu	Asp	Ile	Ala	Pro	Ile	Asp	Asn	Asn	Ser	Asn	Asn	Arg	Tyr	
180					185					190					195	
AGG	TTG	ATA	AGT	TGT	AAC	ACC	TCA	GTC	ATT	ACA	CAG	GCC	TGT	CCA	AAG	1280
Arg	Leu	Ile	Ser	Cys	Asn	Thr	Ser	Val	Ile	Thr	Gln	Ala	Cys	Pro	Lys	
				200					205					210		
GTA	TCC	TTT	GAG	CCA	ATT	CCC	ATA	CAT	TAT	TGT	GCC	CCG	GCT	GGT	TTT	1328
Val	Ser	Phe	Glu	Pro	Ile	Pro	Ile	His	Tyr	Cys	Ala	Pro	Ala	Gly	Phe	
			215					220					225			
GCG	ATT	CTA	AAG	TGT	AAA	GAT	AAG	AAG	TTC	AAT	GGA	AAA	GGA	CCA	TGT	1376
Ala	Ile	Leu	Lys	Cys	Lys	Asp	Lys	Lys	Phe	Asn	Gly	Lys	Gly	Pro	Cys	
		230					235					240				
ACA	AAT	GTC	AGC	ACA	GTA	CAA	TGT	ACA	CAT	GGA	ATT	AGG	CCA	GTA	GTA	1424
Thr	Asn	Val	Ser	Thr	Val	Gln	Cys	Thr	His	Gly	Ile	Arg	Pro	Val	Val	
		245				250						255				
TCA	ACT	CAA	CTG	CTG	TTA	AAT	GGC	AGT	CTA	GCA	GAA	GAA	GAG	GTA	GTA	1472
Ser	Thr	Gln	Leu	Leu	Leu	Asn	Gly	Ser	Leu	Ala	Glu	Glu	Glu	Val	Val	
260					265					270					275	
ATT	AGA	TCC	GCC	AAT	TTC	GCG	GAC	AAT	GCT	AAA	GTC	ATA	ATA	GTA	CAG	1520
Ile	Arg	Ser	Ala	Asn	Phe	Ala	Asp	Asn	Ala	Lys	Val	Ile	Ile	Val	Gln	
				280					285					290		
CTG	AAT	GAA	TCT	GTA	GAA	ATT	AAT	TGT	ACA	AGA	CCC	AAC	AAC	AAT	ACA	1568
Leu	Asn	Glu	Ser	Val	Glu	Ile	Asn	Cys	Thr	Arg	Pro	Asn	Asn	Asn	Thr	
			295					300					305			
AGA	AAA	AGT	ATA	CAT	ATA	GGA	CCA	GGC	AGA	GCA	TTT	TAT	ACA	ACA	GGA	1616
Arg	Lys	Ser	Ile	His	Ile	Gly	Pro	Gly	Arg	Ala	Phe	Tyr	Thr	Thr	Gly	
		310					315					320				
GAA	ATA	ATA	GGA	GAT	ATA	AGA	CAA	GCA	CAT	TGT	AAC	CTT	AGT	AGA	GCA	1664
Glu	Ile	Ile	Gly	Asp	Ile	Arg	Gln	Ala	His	Cys	Asn	Leu	Ser	Arg	Ala	
		325				330					335					
AAA	TGG	AAT	GAC	ACT	TTA	AAT	AAG	ATA	GTT	ATA	AAA	TTA	AGA	GAA	CAA	1712
Lys	Trp	Asn	Asp	Thr	Leu	Asn	Lys	Ile	Val	Ile	Lys	Leu	Arg	Glu	Gln	
340					345					350					355	
TTT	GGG	AAT	AAA	ACA	ATA	GTC	TTT	AAG	CAC	TCC	TCA	GGA	GGG	GAC	CCA	1760
Phe	Gly	Asn	Lys	Thr	Ile	Val	Phe	Lys	His	Ser	Ser	Gly	Gly	Asp	Pro	
				360					365					370		
GAA	ATT	GTG	ACG	CAC	AGT	TTT	AAT	TGT	GGA	GGG	GAA	TTT	TTC	TAC	TGT	1808
Glu	Ile	Val	Thr	His	Ser	Phe	Asn	Cys	Gly	Gly	Glu	Phe	Phe	Tyr	Cys	
			375					380					385			
AAT	TCA	ACA	CAA	CTG	TTT	AAT	AGT	ACT	TGG	AAT	GTT	ACT	GAA	GAG	TCA	1856
Asn	Ser	Thr	Gln	Leu	Phe	Asn	Ser	Thr	Trp	Asn	Val	Thr	Glu	Glu	Ser	
		390					395						400			

AAT AAC ACT GTA GAA AAT AAC ACA ATC ACA CTC CCA TGC AGA ATA AAA 1904
 Asn Asn Thr Val Glu Asn Asn Thr Ile Thr Leu Pro Cys Arg Ile Lys
 405 410 415

CAA ATT ATA AAC ATG TGG CAG GAA GTA GGA AGA GCA ATG TAT GCC CCT 1952
 Gln Ile Ile Asn Met Trp Gln Glu Val Gly Arg Ala Met Tyr Ala Pro
 420 425 430 435

CCC ATC AGA GGA CAA ATT AGA TGT TCA TCA AAT ATT ACA GGG CTG CTA 2000
 Pro Ile Arg Gly Gln Ile Arg Cys Ser Ser Asn Ile Thr Gly Leu Leu
 440 445 450

TTA ACA AGA GAT GGT GGT CCT GAG GAC AAC AAG ACC GAG GTC TTC AGA 2048
 Leu Thr Arg Asp Gly Gly Pro Glu Asp Asn Lys Thr Glu Val Phe Arg
 455 460 465

CCT GGA GGA GGA GAT ATG AGG GAT AAT TGG AGA AGT GAA TTA TAT AAA 2096
 Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys
 470 475 480

TAT AAA GTA GTA AAA ATT GAA CCA TTA GGA GTA GCA CCC ACC AAG GCA 2144
 Tyr Lys Val Val Lys Ile Glu Pro Leu Gly Val Ala Pro Thr Lys Ala
 485 490 495

AAG AGA AGA GTG GTG CAG AGA GAA AAA AGA GCA GTG GGA ATA GGA GCT 2192
 Lys Arg Arg Val Val Gln Arg Glu Lys Arg Ala Val Gly Ile Gly Ala
 500 505 510 515

GTG TTC CTT GGG TTC TTG GGA GCA GCA GGA AGC ACT ATG GGC GCA GCG 2240
 Val Phe Leu Gly Phe Leu Gly Ala Ala Gly Ser Thr Met Gly Ala Ala
 520 525 530

GCA ATG ACG CTG ACG GTA CAG GCC AGA CTA TTA TTG TCT GGT ATA GTG 2288
 Ala Met Thr Leu Thr Val Gln Ala Arg Leu Leu Leu Ser Gly Ile Val
 535 540 545

CAA CAG CAG AAC AAT CTG CTG AGG GCT ATT GAG GCG CAA CAG CAT CTG 2336
 Gln Gln Gln Asn Asn Leu Leu Arg Ala Ile Glu Ala Gln Gln His Leu
 550 555 560

TTG CAA CTC ACA GTC TGG GGC ATC AAG CAG CTC CAG GCA AGA GTC CTG 2384
 Leu Gln Leu Thr Val Trp Gly Ile Lys Gln Leu Gln Ala Arg Val Leu
 565 570 575

GCT GTG GAA AGA TAC CTA AGG GAT CAA CAG CTC CTG GGG ATT TGG GGT 2432
 Ala Val Glu Arg Tyr Leu Arg Asp Gln Gln Leu Leu Gly Ile Trp Gly
 580 585 590 595

TGC TCT GGA AAA CTC ATC TGC ACC ACT GCT GTG CCT TGG AAT GCT AGT 2480
 Cys Ser Gly Lys Leu Ile Cys Thr Thr Ala Val Pro Trp Asn Ala Ser
 600 605 610

TGG AGT AAT AAA TCT CTG AAT AAG ATT TGG GAT AAC ATG ACC TGG ATA 2528
 Trp Ser Asn Lys Ser Leu Asn Lys Ile Trp Asp Asn Met Thr Trp Ile
 615 620 625

GAG TGG GAC AGA GAA ATT AAC AAT TAC ACA AGC ATA ATA TAC AGC TTA 2576
 Glu Trp Asp Arg Glu Ile Asn Asn Tyr Thr Ser Ile Ile Tyr Ser Leu
 630 635 640

ATT GAA GAA TCG CAG AAC CAA CAA GAA AAG AAT GAA CAA GAA TTA TTA 2624
 Ile Glu Glu Ser Gln Asn Gln Gln Glu Lys Asn Glu Gln Glu Leu Leu
 645 650 655

GAA TTA GAT AAA TGG GCA AGT TTG TGG AAT TGG TTT GAC ATA ACA AAA 2672
 Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile Thr Lys
 660 665 670 675

TGG CTG TGG TAT ATA AAA ATA TTC ATA ATG ATA GTA GGA GGC TTG ATA 2720
 Trp Leu Trp Tyr Ile Lys Ile Phe Ile Met Ile Val Gly Gly Leu Ile
 680 685 690

GGT TTA AGA ATA GTT TTT TCT GTA CTT TCT ATA GTG AAT AGA GTT AGG 2768
 Gly Leu Arg Ile Val Phe Ser Val Leu Ser Ile Val Asn Arg Val Arg
 695 700 705

CAG GGA TAC TCA CCA TTA TCG TTT CAG ACC CAC CTC CCA TCC TCG AGG 2816
 Gln Gly Tyr Ser Pro Leu Ser Phe Gln Thr His Leu Pro Ser Ser Arg
 710 715 720

GGA CCC GAC AGG CCC GGA GGA ATC GAA GAA GAA GGT GGA GAG AGA GAC 2864
 Gly Pro Asp Arg Pro Gly Gly Ile Glu Glu Glu Gly Gly Glu Arg Asp
 725 730 735

AGA GAC AGA TCC GGT CCA TTA GTG AAC GGA TTC TTG GCG CTT ATC TGG 2912
 Arg Asp Arg Ser Gly Pro Leu Val Asn Gly Phe Leu Ala Leu Ile Trp
 740 745 750 755

GTC GAT CTG CGG AGC CTG TTC CTC TTC AGC TAC CAC CGC TTG AGA GAC 2960
 Val Asp Leu Arg Ser Leu Phe Leu Phe Ser Tyr His Arg Leu Arg Asp
 760 765 770

TTA CTC TTG ATT GTG ATG AGG ATT GTG GAA CTT CTG GGA CTA GCA GGG 3008
 Leu Leu Leu Ile Val Met Arg Ile Val Glu Leu Leu Gly Leu Ala Gly
 775 780 785

GGG TGG GAA GTC CTC AAA TAT TGG TGG AAT CTC CTA CAG TAT TGG AGT 3056
 Gly Trp Glu Val Leu Lys Tyr Trp Trp Asn Leu Leu Gln Tyr Trp Ser
 790 795 800

CAG GAA CTA AAG AAT AGT GCT GTT AGC TTG CTC AAT GCC ACA GCT GTA 3104
 Gln Glu Leu Lys Asn Ser Ala Val Ser Leu Leu Asn Ala Thr Ala Val
 805 810 815

GCA GTA GCT GAA GGG ACA GAT AGG GTT ATA GAA GTA TTA CAG AGA GCT 3152
 Ala Val Ala Glu Gly Thr Asp Arg Val Ile Glu Val Leu Gln Arg Ala
 820 825 830 835

GTT AGA GCT ATT CTC CAC ATA CCT AGA AGA ATA AGA CAG GGC TTG GAA 3200
 Val Arg Ala Ile Leu His Ile Pro Arg Arg Ile Arg Gln Gly Leu Glu
 840 845 850

AGG GCT TTG CTA TAAGATGGGT GGCAAGTGGT CAAAAGTAG TATAGTCGTA 3252
 Arg Ala Leu Leu
 855

TGGCCTGCTG TAAGGAAAAG AATGAGAAGA ACTGAGCCAG CAGCAGATGG AGTAGGAGCA 3312

GTATCTAGAG ACCTGGAAAA ACATGGAGCA ATCACAAGTA GCAATACAGC AGCTAACAAT 3372

GCTGATTGTG CCTGGCTAGA AGCACAAGAG GATGAAGAAG TGGGTTTTCC AGTCAGACCT 3432

CAGGTACCTT TAAGACCAAT GACTCGCAGT GCAGCTATAG ATCTTAGCCA CTTTTTTAAG 3492

AAAAAGGGGG GACTGGAAGG GCTAATTCAC TCCCAAAAAA GACAAGATAT CCTTGATTG 3552

TGGGTCTACC ACACACAAGG CTAATTCCCT GATTGGCAGA ACTACACACC AGGGCCAGGG 3612

ACCAGATTTC CACTGACCTT TGGATGGTGC TTCAAGCTAG TACCAGTTGA GCCAGAGAAG 3672

GTAGAAGAGG CCAATGAAGG AGAGAACAAC TGCTTGTCAC ACCCTATGAG CCTGCATGGG 3732

ATGGATGACC CGGAGAAAGA AGTGTTAGCA TGGAAGTTTG ACAGCAGCCT AGCATTCCAT 3792

CACGTGGCCC GAGAA 3807

TABLE IIIA

Met	Arg	Val	Thr	Glu	Ile	Arg	Lys	Ser	Tyr	Gln	His	Trp	Trp	Arg	Trp	
1				5					10					15		
Gly	Ile	Met	Leu	Leu	Gly	Ile	Leu	Met	Ile	Cys	Asn	Ala	Glu	Glu	Lys	
		20						25					30			
Leu	Trp	Val	Thr	Val	Tyr	Tyr	Gly	Val	Pro	Val	Trp	Lys	Glu	Ala	Thr	
		35					40					45				
Thr	Thr	Leu	Phe	Cys	Ala	Ser	Asp	Arg	Lys	Ala	Tyr	Asp	Thr	Glu	Val	
	50					55					60					
His	Asn	Val	Trp	Ala	Thr	His	Ala	Cys	Val	Pro	Thr	Asp	Pro	Asn	Pro	
65					70					75					80	
Gln	Glu	Val	Glu	Leu	Lys	Asn	Val	Thr	Glu	Asn	Phe	Asn	Met	Trp	Lys	
			85						90					95		
Asn	Asn	Met	Val	Glu	Gln	Met	His	Glu	Asp	Ile	Ile	Ser	Leu	Trp	Asp	
		100						105					110			
Gln	Ser	Leu	Lys	Pro	Cys	Val	Lys	Leu	Thr	Pro	Leu	Cys	Val	Thr	Leu	
		115					120					125				
Asn	Cys	Thr	Asp	Leu	Arg	Asn	Ala	Thr	Asn	Gly	Asn	Asp	Thr	Asn	Thr	
	130					135					140					
Thr	Ser	Ser	Ser	Arg	Gly	Met	Val	Gly	Gly	Gly	Glu	Met	Lys	Asn	Cys	
145					150				155					160		
Ser	Phe	Asn	Ile	Thr	Thr	Asn	Ile	Arg	Gly	Lys	Val	Gln	Lys	Glu	Tyr	
			165						170					175		
Ala	Leu	Phe	Tyr	Lys	Leu	Asp	Ile	Ala	Pro	Ile	Asp	Asn	Asn	Ser	Asn	
		180						185					190			
Asn	Arg	Tyr	Arg	Leu	Ile	Ser	Cys	Asn	Thr	Ser	Val	Ile	Thr	Gln	Ala	
		195					200					205				
Cys	Pro	Lys	Val	Ser	Phe	Glu	Pro	Ile	Pro	Ile	His	Tyr	Cys	Ala	Pro	
	210					215					220					
Ala	Gly	Phe	Ala	Ile	Leu	Lys	Cys	Lys	Asp	Lys	Lys	Phe	Asn	Gly	Lys	
225				230					235					240		
Gly	Pro	Cys	Thr	Asn	Val	Ser	Thr	Val	Gln	Cys	Thr	His	Gly	Ile	Arg	
			245						250					255		
Pro	Val	Val	Ser	Thr	Gln	Leu	Leu	Leu	Asn	Gly	Ser	Leu	Ala	Glu	Glu	
		260					265						270			
Glu	Val	Val	Ile	Arg	Ser	Ala	Asn	Phe	Ala	Asp	Asn	Ala	Lys	Val	Ile	
	275						280					285				
Ile	Val	Gln	Leu	Asn	Glu	Ser	Val	Glu	Ile	Asn	Cys	Thr	Arg	Pro	Asn	
	290					295					300					
Asn	Asn	Thr	Arg	Lys	Ser	Ile	His	Ile	Gly	Pro	Gly	Arg	Ala	Phe	Tyr	
305					310					315					320	

WO 92/06990

PCT/US91/07611

36

Thr Thr Gly Glu Ile Ile Gly Asp Ile Arg Gln Ala His Cys Asn Leu
 325 330 335
 Ser Arg Ala Lys Trp Asn Asp Thr Leu Asn Lys Ile Val Ile Lys Leu
 340 345 350
 Arg Glu Gln Phe Gly Asn Lys Thr Ile Val Phe Lys His Ser Ser Gly
 355 360 365
 Gly Asp Pro Glu Ile Val Thr His Ser Phe Asn Cys Gly Gly Glu Phe
 370 375 380
 Phe Tyr Cys Asn Ser Thr Gln Leu Phe Asn Ser Thr Trp Asn Val Thr
 385 390 395 400
 Glu Glu Ser Asn Asn Thr Val Glu Asn Asn Thr Ile Thr Leu Pro Cys
 405 410 415
 Arg Ile Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Arg Ala Met
 420 425 430
 Tyr Ala Pro Pro Ile Arg Gly Gln Ile Arg Cys Ser Ser Asn Ile Thr
 435 440 445
 Gly Leu Leu Leu Thr Arg Asp Gly Gly Pro Glu Asp Asn Lys Thr Glu
 450 455 460
 Val Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser Glu
 465 470 475 480
 Leu Tyr Lys Tyr Lys Val Val Lys Ile Glu Pro Leu Gly Val Ala Pro
 485 490 495
 Thr Lys Ala Lys Arg Arg Val Val Gln Arg Glu Lys Arg Ala Val Gly
 500 505 510
 Ile Gly Ala Val Phe Leu Gly Phe Leu Gly Ala Ala Gly Ser Thr Met
 515 520 525
 Gly Ala Ala Ala Met Thr Leu Thr Val Gln Ala Arg Leu Leu Leu Ser
 530 535 540
 Gly Ile Val Gln Gln Gln Asn Asn Leu Leu Arg Ala Ile Glu Ala Gln
 545 550 555 560
 Gln His Leu Leu Gln Leu Thr Val Trp Gly Ile Lys Gln Leu Gln Ala
 565 570 575
 Arg Val Leu Ala Val Glu Arg Tyr Leu Arg Asp Gln Gln Leu Leu Gly
 580 585 590
 Ile Trp Gly Cys Ser Gly Lys Leu Ile Cys Thr Thr Ala Val Pro Trp
 595 600 605
 Asn Ala Ser Trp Ser Asn Lys Ser Leu Asn Lys Ile Trp Asp Asn Met
 610 615 620
 Thr Trp Ile Glu Trp Asp Arg Glu Ile Asn Asn Tyr Thr Ser Ile Ile
 625 630 635 640
 Tyr Ser Leu Ile Glu Glu Ser Gln Asn Gln Gln Glu Lys Asn Glu Gln
 645 650 655
 Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn Trp Phe Asp
 660 665 670

2093427

37

[illegible]

CLAIMS:

1. A DNA construct that is capable of yielding, after being introduced into a recipient cell, an active HIV-1 strain, said HIV-1 strain being MN-ST1, obtained from a molecular clone deposited as ATCC accession number 40889 and having the genomic structure as set forth in Figure 3.
2. A DNA construct consisting essentially of the HIV -1 strain BA-L virus envelope and rev domains as structurally set forth in Figure 4, said DNA construct deposited as ATCC accession number 40890.
3. The DNA construct of claim 1, wherein said DNA construct has the nucleic acid sequence set forth in Table II.
4. A portion of the DNA construct as defined in claim 3, said portion containing a nucleic acid sequence encoding the MN-ST1 envelope protein having 857 amino acids as set forth in Table II.
5. A portion of the DNA construct as defined in claim 4, said portion containing a nucleic acid sequence from nucleotide position 6243 to nucleotide position 8813 as set forth in Table II and encoding the MN-ST1 envelope protein.
6. A DNA construct consisting essentially of the HIV-1 strain BA-L virus envelope and rev domains encoded by the nucleic acid sequence of plasmid pBA-L as set forth in Table III, said plasmid BA-L deposited as ATCC accession number 40890.
7. A portion of the DNA construct as defined in claim 6, said portion containing a nucleic acid sequence encoding the BA-L envelope protein having 855 amino acids as set forth in Table III.
8. A portion of the DNA construct as defined in claim 7, said portion containing a nucleic acid sequence from nucleotide position 648 to nucleotide position 3212 as set forth in Table III and encoding the BA-L envelope protein.
9. A DNA construct comprising the nucleic acid sequence as defined in claim 3 and a vector.
10. A DNA construct comprising the nucleic acid sequence as defined in claim 4 or claim 5 and a vector.

11. A DNA construct comprising the nucleic acid sequence as defined in claim 7 or claim 8 and a vector.
12. The DNA construct as defined in claim 10, further comprising a DNA segment encoding a *rev* protein and a *rev*-responsive region.
13. The DNA construct as defined in claim 11, further comprising a DNA segment encoding a *rev* protein and a *rev*-responsive region.
14. An isolated DNA molecule having the nucleotide sequence 170 to 3318 of Table III and encoding the envelope gene of HIV-1 strain BA-L.
15. A host cell stably transformed with the DNA construct as defined in claim 9.
16. A host cell stably transformed with the DNA construct as defined in claim 10, which allows expression of the encoded viral protein.
17. A host cell stably transformed with the DNA construct as defined in claim 11, which allows expression of the encoded viral protein.
18. A host cell stably transformed with the DNA construct as defined in claim 12, which allows expression of the encoded viral protein.
19. A host cell stably transformed with the DNA construct as defined in claim 13, which allows expression of the encoded viral protein.
20. A host cell transformed or transfected with DNA encoding HIV-1 virus strain MN-STI, said MN-STI virus strain having the DNA sequence given in Table II.
21. A host cell transformed or transfected with DNA encoding the envelope protein of HIV-1 virus strain BA-L, said BA-L envelope encoding DNA having the nucleic acid sequence given in Table III.
22. A virus particle produced by the host cell according to claim 20.
23. Use of a recombinantly-produced envelope protein having the amino acid sequence set forth in Table II or an immunogenic fragment thereof, and encoded by the envelope gene of molecularly-cloned HIV-1 strain MN-STI, said molecularly-cloned MN-STI strain deposited as ATCC accession number 40889, as an immunogen, as a vaccine or a component thereof, as an agent in immunotherapeutic treatment of individuals

infected with HIV-1 or as bioassays or a component thereof for detection of HIV-1 infection.

24. Use of a recombinantly-produced envelope protein having the amino acid sequence set forth in Table III or an immunogenic fragment thereof, and encoded by the envelope gene of HIV-1 strain BA-L, said molecularly cloned BA-L envelope region deposited as ATCC accession number 40890, as an immunogen, as a vaccine or a component thereof, as an agent in immunotherapeutic treatment of individuals infected with HIV-1 or as bioassays or a component thereof for detection of HIV-1 infection.

25. A method of producing a viral protein of the MN-STI strain of HIV-1, comprising:

- a) culturing host cells as defined in claim 15, claim 16, or claim 18.
- b) expressing the viral protein; and
- c) isolating the viral protein.

26. The method according to claim 25, wherein the MN-STI viral protein is envelope protein.

27. A method of producing a viral envelope protein of the BA-L strain of HIV-1, comprising:

- a) culturing host cells as defined in claim 17 or claim 19.
- b) expressing the viral protein; and
- c) isolating the viral protein.

28. A bioassay for detecting HIV-1 in a biological sample, comprising the steps of:

- a) contacting the biological sample with an envelope protein obtained from the molecular clone as defined in any one of claims 1 to 8, said envelope protein coated onto a surface;
- b) allowing a complex to form between the protein and antibodies specific therefore, if present in the sample; and
- c) detecting the presence or absence of the complex of step b).

29. The bioassay according to claim 28, wherein the detecting is performed by fluorescence absorption spectroscopy or colorimetry.

2093427




FIG. 1

2/7

2093427





FIG. 2

2093427



STRUCTURE AND RESTRICTION MAP
OF LAMBDA MN-ST1

FIG.3

2093427

STRUCTURE OF λ BA-L1

Hiv-1(BA-L)




FIG.4




FIG.5A

6/7

2093427




FIG.5B

2093427

7/7

BAFINAL




FIG.5C

SUBSTITUTE SHEET

